

1 **Single-cell profiling of tuberculosis lung granulomas reveals functional lymphocyte**  
2 **signatures of bacterial control**

3  
4 **Authors:**

5 Hannah P. Gideon<sup>1,2\*</sup>, Travis K. Hughes<sup>3,4,5\*</sup>, Marc H. Wadsworth II<sup>3,4,5,6</sup>, Ang Andy Tu<sup>7</sup>, Todd  
6 M. Gierahn<sup>7</sup>, Forrest F. Hopkins<sup>4,8</sup>, Jun-Rong Wei<sup>4,8</sup>, Conner Kummerlowe<sup>9</sup>, Nicole L. Grant<sup>1</sup>,  
7 Kievershen Nargan<sup>10</sup>, JiaYao Phuah<sup>1</sup>, H. Jacob Borish<sup>1</sup>, Pauline Maiello<sup>1</sup>, Alexander G. White<sup>1</sup>,  
8 Sharie Keanne C. Ganchua<sup>1</sup>, Amy Myers<sup>1</sup>, Cassandra L. Ameal<sup>1</sup>, Catherine T. Cochran<sup>1</sup>,  
9 Sarah K. Nyquist<sup>3,4,5,9,12</sup>, Joshua M. Peters<sup>4,7</sup>, Jaime A Tomko<sup>1</sup>, Lonnie James Frye<sup>1</sup>, Jacob M.  
10 Rosenberg<sup>4,8,11</sup>, Angela Shih<sup>11</sup>, Michael Chao<sup>4,8</sup>, Charles A. Scanga<sup>1,2</sup>, Jose Ordovas-  
11 Montanes<sup>4,5</sup>, Bonnie Berger<sup>12</sup>, Joshua T. Mattila<sup>2,13</sup>, Rajhmun Madansein<sup>14</sup>, J. Christopher  
12 Love<sup>4,15,16</sup>, Bryan Bryson<sup>4,7</sup>, Philana Ling Lin<sup>2,17</sup>, Alasdair Leslie<sup>10,18,19</sup>, Samuel M. Behar<sup>20</sup>,  
13 JoAnne L Flynn<sup>1,2#</sup>, Sarah M. Fortune<sup>4,5,8#</sup>, Alex Shalek<sup>3,4,5,6,16#</sup>

14  
15 **\*These first authors contributed equally to this work.**

16 **#These last authors contributed equally to this work.**

17 **Authors Affiliation:**

- 18 1. Department of Microbiology and Molecular Genetics, University of Pittsburgh School of  
19 Medicine, Pittsburgh PA USA  
20 2. Center for Vaccine Research, University of Pittsburgh, Pittsburgh PA USA  
21 3. Institute for Medical Engineering & Science, Massachusetts Institute of Technology,  
22 Cambridge, MA  
23 4. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA  
24 5. Broad Institute of MIT and Harvard, Cambridge, MA  
25 6. Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA  
26 7. Department of Biological Engineering, Massachusetts Institute of Technology,  
27 Cambridge, MA  
28 8. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of  
29 Public Health, Boston, Massachusetts, USA  
30 9. Program in Computational and Systems Biology, Massachusetts Institute of Technology,  
31 Cambridge, MA, USA.  
32 10. Africa Health Research Institute, Durban, South Africa  
33 11. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA

- 34 12. Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of  
35 Technology, Cambridge, MA, USA.
- 36 13. Department of Infectious Diseases and Microbiology, Graduate School of Public Health,  
37 University of Pittsburgh, Pittsburgh, PA
- 38 14. Department of Cardiothoracic Surgery, University of KwaZulu Natal, Durban, South  
39 Africa
- 40 15. Department of Chemical Engineering, Massachusetts Institute of Technology,  
41 Cambridge, Massachusetts, United States
- 42 16. The Koch Institute for Integrative Cancer Research, Massachusetts Institute of  
43 Technology, Cambridge, Massachusetts, United States
- 44 17. Department of Pediatrics, University of Pittsburgh School of Medicine, UPMC Children's  
45 Hospital of Pittsburgh, Pittsburgh PA USA
- 46 18. School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal,  
47 Durban, South Africa.
- 48 19. Department of Infection and Immunity, University College London, London, United  
49 Kingdom
- 50 20. Department of Microbiology and Physiological Systems, University of Massachusetts  
51 Medical School, Worcester, Massachusetts, USA  
52

53 **Abstract**

54 In humans and nonhuman primates, *Mycobacterium tuberculosis* lung infection yields a complex  
55 multicellular structure—the tuberculosis granuloma. All granulomas are not equivalent,  
56 however, even within the same host: in some, local immune activity promotes bacterial  
57 clearance, while in others, it allows persistence or outgrowth. Here, we used single-cell RNA-  
58 sequencing to define holistically cellular responses associated with control in cynomolgus  
59 macaques. Granulomas that facilitated bacterial killing contained significantly higher  
60 proportions of *CD4+* and *CD8+* T cells expressing hybrid Type1-Type17 immune responses or  
61 stem-like features and *CD8*-enriched T cells with specific cytotoxic functions; failure to control  
62 correlated with mast cell, plasma cell and fibroblast abundance. Co-registering these data with  
63 serial PET-CT imaging suggests that a degree of early immune control can be achieved through  
64 cytotoxic activity, but that more robust restriction only arises after the priming of specific  
65 adaptive immune responses, defining new targets for vaccination and treatment.

66

67 **Introduction**

68 Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (Mtb), remains a major global health  
69 threat. It is estimated that one quarter of the world's population is infected with Mtb, and 10  
70 million new cases and 1.5 million deaths due to TB were reported in 2019 (WHO, 2019). More  
71 than 90% of those infected do not progress to active disease. Thus, protective immune  
72 responses against Mtb appear to be relatively common in humans, but have been difficult to  
73 dissect because of our inability to measure immune responses in lung tissue and to distinguish  
74 the true extent of bacterial control in people. Understanding the cellular and molecular features  
75 associated with protective immunity, as well as those that lead to failure to control infection, is  
76 critical for the development of next-generation cures and preventions for TB.

77  
78 Mtb infection in humans and nonhuman primates (NHP) is characterized by the formation of  
79 granulomas predominantly in the lungs and lymph nodes (Flynn, 2010; Lin et al., 2014b; Russell  
80 et al., 2010; Ulrichs and Kaufmann, 2006). TB lung granulomas are spatially organized  
81 structures (**Figure 1A**), well circumscribed from the lung parenchyma and comprised of a  
82 combination of parenchymal, stromal, and immune cells, such as macrophages, neutrophils, T  
83 cells, B cells and plasma cells (Ehlers and Schaible, 2012; Flynn, 2010; Gideon et al., 2019; Lin  
84 et al., 2006; Mattila et al., 2013; Pagan and Ramakrishnan, 2014; Phuah et al., 2012; Reece  
85 and Kaufmann, 2012; Ulrichs and Kaufmann, 2006). A spectrum of granuloma types,  
86 organization and cellular composition have been described in both humans and NHP (Canetti,  
87 1955; Flynn, 2010; Hunter, 2011, 2016; Lin et al., 2006).

88  
89 The cynomolgus macaque NHP model of Mtb infection has been critical for characterizing the  
90 cellular and molecular features that underlie granuloma fate since it recapitulates the spectrum  
91 of human infection outcomes, disease and pathology (Canetti, 1955; Flynn, 2010; Lin et al.,  
92 2006) and. Human granulomas are typically available only from surgical resections in cases



93 where drug treatment fails and thus do not allow analysis of successful immune clearance.  
94 Most murine models, meanwhile, do not develop human-like granulomas, and mice are not  
95 particularly adept at killing Mtb bacilli in the lungs, which makes identifying features associated  
96 with immune mediated clearance difficult (Flynn et al., 2015; Flynn, 2010; Langermans et al.,  
97 2001; Verreck et al., 2009; Zhan et al., 2017).

98

99 Studies of Mtb infection in NHP have demonstrated that individual granulomas are dynamic  
100 (Coleman et al., 2014b; Lin et al., 2013; Lin et al., 2014b), changing with the evolving  
101 interactions between bacteria and diverse host cell types (Ehlers and Schaible, 2012; Flynn et  
102 al., 2003; Flynn, 2010; Mattila et al., 2013; Phuah et al., 2012; Ulrichs and Kaufmann, 2006).

103 The bacterial burden in individual granulomas is highest early in infection and then decreases  
104 due to increased killing as the immune response evolves, even in animals that ultimately  
105 develop active TB (**Figure S1A-B**) (Cadena et al., 2016; Lin et al., 2014b; Maiello et al., 2018).

106 Strikingly, however, individual granulomas within a single host follow independent trajectories  
107 with respect to inflammation, cellular composition, reactivation risk, and ability to kill Mtb  
108 (Coleman et al., 2014b; Gideon et al., 2015; Lenaerts et al., 2015; Lin et al., 2013; Lin et al.,  
109 2014b; Malherbe et al., 2016; Martin et al., 2017). We and others have systematically profiled

110 cellular immune responses of individual cell types in macaque lung granulomas, including T  
111 cells (Diedrich et al., 2020; Foreman et al., 2016; Gideon et al., 2015; Lin et al., 2012; Mattila et  
112 al., 2011; Wong et al., 2018), macrophages (Mattila et al., 2013), B cells (Phuah et al., 2016;  
113 Phuah et al., 2012), and neutrophils (Gideon et al., 2019; Mattila et al., 2015), and examined the

114 instructive roles of cytokines including IFN- $\gamma$ , IL-2, TNF, IL-17 and IL-10 (Gideon et al., 2015; Lin  
115 et al., 2010; Wong et al., 2020). These analyses have enabled key insights into how specific

116 canonical cell types and effector molecules relate to bacterial burden; for example, they  
117 revealed that balanced production of pro- and anti-inflammatory cytokines by granuloma T cells  
118 associates with bacterial control. However, each analysis has been relatively narrow in focus

119 and we have little understanding of how the collective actions of diverse cell types within  
120 individual granulomas shape outcome.

121  
122 The recent emergence of high-throughput single-cell genomic profiling methods affords  
123 transformative opportunities to define the cell types, phenotypic states and intercellular circuits  
124 that comprise granulomas and inform their dynamics (Prakadan et al., 2017). Rather than  
125 forcing selection of distinct cellular subsets or features of interest *a priori*, single-cell RNA-Seq  
126 (scRNA-seq) can be applied to examine comprehensively the cellular constituents of complex  
127 multicellular structures and their functional attributes. Illustratively, single-cell transcriptomics  
128 has been used to identify fundamental alterations in cellular ecosystems associated with the  
129 severity and persistence of inflammation (Ordovas-Montanes et al., 2018; Smillie et al., 2019),  
130 the cellular bases of disease (Kazer et al., 2020; Montoro et al., 2018) and responses to it, and  
131 actionable features of the tumor-immune microenvironment (Hovestadt et al., 2019; Tirosh et  
132 al., 2016). While scRNA-seq has been applied to understand peripheral immune or *in vitro*  
133 responses in Mtb infection (Gierahn et al., 2017; Huang et al., 2019; Nathan et al., 2020), it has  
134 yet to be leveraged to empower global analyses of cellular responses linked to bacterial control  
135 in TB lung granulomas, potentially given challenges associated with tracking, identifying, and  
136 isolating these small heterogeneous structures from NHP in a biosafety-level 3 suite.

137  
138 Here, to characterize the relationship between the cellular features of TB lung granulomas and  
139 bacterial burden explicitly, we applied the Seq-Well platform for massively-parallel single-cell  
140 RNA-Seq (scRNA-seq) (Gierahn et al., 2017) to generate single-cell transcriptional profiles of  
141 pulmonary Mtb granulomas at 10 weeks post infection (p.i.; **Figure 1A**) in cynomolgus  
142 macaques. Individual granulomas displayed a broad range of bacterial burdens from restrictive  
143 (sterile, 0 colony forming units (CFU) – i.e., culturable live bacterial burden) to permissive (high,  
144 ~80,000 CFU), enabling us to define cellular compositions and effector functions that associate

145 with bacterial control. With these data, based on unbiased gene-expression analysis, we  
146 discovered several previously unappreciated functional cellular phenotypes that are temporally  
147 associated with bacterial control – including hybrid T1-T17 CD4+ and CD8+ states, cytotoxic T  
148 and NK subsets, mast, and plasma cells – and validate select observations and extend to  
149 humans via orthogonal techniques. Collectively, our data provide a global view of the TB lung  
150 granuloma cellular microenvironments in which Mtb is either controlled or persists, suggesting  
151 several novel therapeutic and prophylactic targets for future investigation.

152 **Results**

153 **Study design and bacterial burden in granulomas**

154 We sought to comprehensively define the complex cellular ecosystems (**Figure 1A**) of  
155 granulomas that manifested different degrees of bacterial control in NHP. Four cynomolgus  
156 macaques were bronchoscopically infected with a low dose of Mtb (<10 CFU; Erdman strain)  
157 and followed for 10 weeks (**Figure 1B**). The 10-week timepoint represents the first time at  
158 which a significant reduction in average granuloma-level bacterial burden is observed,  
159 compared to peak burden at 4 or 6 weeks post infection (p.i.) (**Figure S1A-B**). Progression of  
160 Mtb infection and granuloma formation were monitored using PET-CT scans at 4, 8, and 10  
161 weeks p.i. For each animal, we quantified total lung FDG activity (**Figure 1C**) from PET-CT  
162 scans as a proxy for overall inflammation (Coleman et al., 2014b; White et al., 2017). At  
163 necropsy, individual PET-CT identified lung granulomas were excised and dissociated to obtain  
164 a single-cell suspension (**STAR\* Methods**).

165  
166 Twenty-six granulomas from the four animals were randomly selected for profiling by scRNA-  
167 seq. For each, we further quantified viable bacterial burden (CFU – i.e., culturable live bacterial  
168 burden) and cumulative (live + dead) bacterial load (chromosomal equivalents, CEQ) (Lin et al.,  
169 2014b; Munoz-Elias et al., 2005) (**Table S1, STAR\* Methods**). Among the 26 granulomas,  
170 there was a range of granuloma-level bacterial burdens, from sterile (0 CFU/granuloma) to high  
171 burden ( $4.6 \log_{10}$  CFU/granuloma) lesions (**Figure 1D**). We analyzed the granulomas using  
172 CFU both as a continuous variable and by binning it into tertiles (Low: 0-500 CFU, n=10; Mid:  
173 500-5000 CFU, n=10; and High: >5000 CFU, n=6) which displayed significant differences in  
174 bacterial burden (low-CFU: median  $1.9 \log_{10}$  CFU/granuloma, mid-CFU  $3.4 \log_{10}$   
175 CFU/granuloma, high-CFU:  $4.2 \log_{10}$  CFU/granuloma;  $p < 0.0001$ , Kruskal-Wallis test with Dunn's  
176 multiple testing correction) (**Figure 1E and Table S1**).

177

178 We evaluated cumulative bacterial burden (chromosomal equivalents, CEQ – derived from live  
179 + dead Mtb) to determine whether low CFU reflected reduced bacterial growth or increased  
180 bacterial killing (Cadena et al., 2018; Lin et al., 2014b; Munoz-Elias et al., 2005). We observed  
181 no significant difference in CEQ values between granulomas with low and high CFU ( $p > 0.99$ ,  
182 Kruskal-Wallis test with Dunn's multiple testing correction) (**Figure 1F**), indicating that  
183 granulomas supported roughly similar cumulative Mtb growth over the course of infection. To  
184 quantify the extent of bacterial killing, we calculated the ratio of CFU to CEQ (**Figure 1G**;  
185 **STAR\* Methods**). Granulomas with the lowest bacterial burdens had significantly higher killing  
186 ( $-2.1 \log_{10}$  CFU/CEQ per granuloma) than those with the highest bacterial burden ( $-0.63 \log_{10}$   
187 CFU/CEQ per granuloma,  $p = 0.0051$ , Kruskal-Wallis test with Dunn's multiple testing correction;  
188 **Figure 1G**).

189

### 190 ***Cellular composition of TB lung Granulomas***

191 To identify cellular and molecular factors associated with increased Mtb killing in an unbiased  
192 fashion, we applied a single-cell suspension from each granuloma to a Seq-Well array  
193 preloaded with barcoded mRNA capture beads under Biosafety Level 3 conditions, and  
194 processed and sequenced as previously described (**STAR\* Methods**) (Gierahn et al., 2017).  
195 After aligning the data to the *Macaca fascicularis* (cynomolgus macaque) genome and  
196 performing robust quality controls and granuloma-specific technical corrections, we retained  
197 109,584 high-quality single-cell transcriptomes for downstream analysis (**Figure S2**; **Table S2**;  
198 **STAR\* Methods**).

199

200 Unsupervised investigation of these data revealed 24 distinct clusters, which we assigned to  
201 canonical cell types using a combination of manual curation and reference gene expression  
202 signatures from the Tabula Muris (Tabula Muris et al., 2018), Mouse Cell Atlas (Han et al.,  
203 2018) and SaVanT database (Lopez et al., 2017) (**Figure S3 A-H**; **STAR\* Methods**). Based on

204 shared expression of genes associated with canonical cell types, we reduced these 24 clusters  
205 to 13 general cell type clusters (**Figures 2A** and **S3G-H**). These encompass groups of  
206 lymphocytes, including B cells (defined by expression of *MS4A1*, *CD79B*, & *BANK1*), T and NK  
207 cells (T/NK; *GNLY*, *TRAC*, *CD3D*, & *GZMH*) and plasma cells (*IGHG1* & *JCHAIN*); myeloid  
208 cells, including conventional dendritic cells (cDCs; *CLEC9A*, *CST3*, & *CPVL*), plasmacytoid  
209 dendritic cells (pDCs; *LILRA4* and *IRF8*) and macrophages (*APOC1*, *LYZ*, and *APOE*); mast  
210 cells (*CPA3* & *TPSAB1*); neutrophils (*CCL2*, *CXCL8*, & *CSF3R*); erythroid cells (*HBA1* & *HBB*);  
211 stromal cells, including endothelial cells (*RNASE1*, *EPAS1*, & *FCN3*) and fibroblasts (*COL3A1*,  
212 *COL1A1*, & *DCN*); Type-1 pneumocytes (*AGER*); and, Type-2 pneumocytes (*SFTPC*, *SFTPB*,  
213 and *SFTPA1*) (**Figure 2A & B**, **Figure S3G-H** and **Table S3**).

214

#### 215 ***Granuloma cellular composition is associated with bacterial burden***

216 To investigate the relationship between cell type composition and bacterial burden, we  
217 quantified the correlation between cellular frequency and CFU across all granulomas (**Figure**  
218 **2C**, **Figure S3I**, **Table S8**). We also assessed differences in cell type proportions between  
219 granulomas with low and high bacterial burden (**Figure 2D**, **Table S8**), and relied on this  
220 analytic approach for some sub-state analyses where our granuloma numbers were too small to  
221 perform a robust correlation analysis. The associations identified when the extent of bacterial  
222 killing was treated as a discrete variable were highly consistent with those identified when it was  
223 treated as a continuous variable (**STAR\* Methods**).

224

225 There was a negative correlation between bacterial burden and the proportion of cells from the  
226 unified T and NK cell cluster, and surprising positive correlations between bacterial burden and  
227 plasma cells, endothelial cells, mast cells, fibroblasts and type-1 pneumocytes (**Figure 2C-D**,  
228 **Table S8A**). We did not observe a significant association between macrophage abundance and

229 bacterial burden. This was true when we examined all 27,670 macrophages as a single cluster,  
230 or when we assessed each of the 9 macrophage sub-clusters identified through further analysis  
231 to resolve their substantial heterogeneity, as reported in other studies (Zilionis et al., 2019)  
232 **(Figure S4 and Table S4; STAR\* Methods)**.

233

### 234 ***T and NK cells as mediators of protection***

235 Our initial analysis revealed a unified T and NK cell cluster that was, in aggregate, the only cell  
236 population negatively correlated with bacterial burden **(Figure 2C-D)**. Data from human and  
237 animal models (including NHPs) suggest an important role for diverse lymphocyte populations in  
238 controlling Mtb infection. In addition to compelling evidence for the importance of conventional  
239 CD4+ and CD8+ T cells (Chen et al., 2009; Foreman et al., 2016; Lin and Flynn, 2015; Lin et  
240 al., 2012; Moguees et al., 2001), other lymphocyte populations have been implicated in control  
241 including gamma delta ( $\gamma\delta$ ) T cells (Ogongo et al., 2020; Shen et al., 2019), iNKT cells (Arora et  
242 al., 2013; Chackerian et al., 2002; Chancellor et al., 2017), donor-unrestricted T cells such as  
243 MAITs (Joosten et al., 2019), innate lymphoid cells (ILC) (Ardain et al., 2019) and cytotoxic  
244 lymphocytes including NK cells (Lin and Flynn, 2015; Portevin et al., 2012; Roy Chowdhury et  
245 al., 2018).

246

247 To further assess functional diversity within the 41,622 cells that comprise T and NK cell cluster,  
248 we performed additional analysis and identified 13 subclusters (designated numerically in  
249 **Figure 3A and S5 Table S6; STAR\* Methods**). We annotated each subcluster of the unified T  
250 and NK cluster based upon enrichment of distinct transcriptional features **(Figure 3C)**, focusing  
251 on those that associate with bacterial control. The abundance of 6 subclusters was negatively  
252 correlated with bacterial burden **(Figure 3D, Table S8b)**; of these, 4 are relatively abundant  
253 clusters comprising 2.4-8.7% of all granuloma cells while 2 constitute less than 1% of all

254 granuloma cells (**Table S4c**). There were no T and NK subclusters that positively correlated  
255 with bacterial burden.

256

257 To further describe each subcluster and identify features that associate with bacterial control,  
258 we first examined the expression of lineage defining markers, known cytotoxic, regulatory,  
259 proliferation genes and T cell transcription factors (**Figure 3C** and **Figure S5D-F**) and  
260 assessed TCR constant gene (*TRAC*, *TRBC* and *TRDC*) expression (**Figure 3B**). The process  
261 of annotation revealed that most of the agnostically defined subclusters did not correspond  
262 neatly to canonical T and NK cell populations. Where possible, we annotate subclusters based  
263 on known T cell markers and literature derived genes of interest but these are parts of broader  
264 transcriptional signatures that appear to reflect dominant cellular response states superimposed  
265 on cell lineage-associated gene expression programs.

266

### 267 ***A prominent role for Type1-Type 17 T cells in bacterial control***

268 T and NK subcluster 13 was the most abundant cell type across all granulomas (8.8%) and the  
269 strongest correlate of control (**Figure 3A,D; Table S4c & S8b**). In this subcluster, we observe  
270 enriched expression of classical Th1-associated genes including *IFNG* and *TNF* (Raphael et al.,  
271 2015), as well as elevated expression of transcription factors associated with Th17  
272 differentiation (Yosef et al., 2013) including *RORA* (Yang et al., 2008), *RORC* (Ivanov et al.,  
273 2006), *RBPJ* (Meyer Zu Horste et al., 2016) and *BHLHE40* (Huynh et al., 2018; Lin et al., 2016;  
274 Lin et al., 2014a). Although this subcluster is also enriched for additional features of Th17 cells  
275 including *CCR6* (Hirota et al., 2007) and *IL23R* (Kobayashi et al., 2008), we do not observe  
276 expression of *IL17A* or *IL17F* (**Figure 4A; Table S6**).

277

278 This hybrid gene expression state is consistent with previously described expression programs  
279 for Th1\* or ex-Th17 cells. Th1\* cells are a subset of Th1 cells, characterized by expression of



280 *CCR6* and *CXCR3*, that co-express IFN- $\gamma$  and T-bet in addition to ROR $\gamma$ t, and are postulated to  
281 play a role in antigen-specific memory (Acosta-Rodriguez et al., 2007), and in human blood,  
282 memory CD4 T cells with a Th1\* expression profile were enriched in individuals with latent TB  
283 compared to uninfected controls (Burel et al., 2018). Ex-Th17 cells, meanwhile, represent  
284 precursors to long-lived tissue-resident memory, characterized by increased expression of  
285 *RBPJ*, *BHLHE40*, *IL23R* and *IL7R* and minimal ROR- $\gamma$ T and IL-17 (Amezcuca Vesely et al.,  
286 2019). Previous studies have revealed a prominent role for CD4 Th1 and Th17 cytokines in  
287 control of Mtb infection, including IFN- $\gamma$ , TNF, and IL-17 (Algood et al., 2005; Green et al., 2013;  
288 Khader et al., 2007; Khader and Gopal, 2010; Lin et al., 2007; Lyadova and Panteleev, 2015;  
289 Millington et al., 2007; O'Garra et al., 2013; Scriba et al., 2017), and studies in NHP granulomas  
290 suggest an association between T1 and T17 cytokine expression and bacterial burden (Gideon  
291 et al., 2015). In addition, in murine models, *BHLHE40* is required for control of Mtb infection, as  
292 a repressor of IL-10 production (Huynh et al., 2018).

293

294 While Th1\* and exTH17 subsets have been described primarily as CD4 T cells, this T1-T17  
295 subcluster is characterized by the expression of both *CD4* and *CD8A/B* transcripts (**Figure 3C**,  
296 **Figure S5D-E**). Moreover, when we compared the gene expression patterns of CD4 and CD8  
297 expressing cells in the subcluster, we noted differential expression of biologically relevant  
298 genes. We therefore questioned whether this subcluster might consist of subpopulations of  
299 cells representing canonical cell types. Upon further subclustering of 9,234 T1-T17 cells, we  
300 identified 4 distinct subpopulations (**Figure 4B**, **Table S7**). Critically, each expresses genes  
301 associated with a Th1\* or ex-Th17 state including *IL23R*, *CCR6*, and *CXCR3*, as well as *RBPJ*,  
302 *BHLHE40*, *FURIN*, *RORA* and *COTL1*. However, each subpopulation also expresses unique  
303 transcriptional programming. Specifically, T1-T17 subpopulation 1 is characterized by  
304 expression of *CD4* and markers of activation and motility including *IL7R*, *CD6*, *TXNIP*, *PDE4D*,

305 *ZFP36L2*, *ITGB1*, *CCR6* and *CXCR3* (**Figure 4C-D**), and has distinct transcriptional overlap  
306 with T and NK subcluster 7 (stem-like cells, described below). Although we cannot confidently  
307 assign effector functions to this subpopulation from the transcriptional data, they are reminiscent  
308 of memory cells with restrained metabolic activity and cytokine expression. T1-T17  
309 subpopulation 2 is characterized by increased relative expression of cytotoxic effector  
310 molecules including *GZMA*, *GZMH*, *GZMK*, *GNLY*, *PRF1*, *KLRC1* and both *CD8A* and *CD8B*  
311 (**Figure 4C-D**). T1-T17 subpopulation 3, which includes cells expressing *CD8A/B* or *CD4*, is  
312 characterized by cytokine gene expression (*IFNG*, *TNF*, *LTA*, and *LTB*), markers of an inhibitory  
313 cell state (*CTLA4*, *GADD45B* and *SLA*) and expression of genes implicated in glycolysis and  
314 mTOR signaling (*TPI1*, *PKM HSPA5*, *ENO1*) (**Figure 4C-D**). T1-T17 subpopulation 4 is very  
315 low in abundance and characterized by heat shock and DNA damage associated transcripts  
316 (*DNAJB1* and *HSPH1*) (**Figure 4, Table S4D**).

317  
318 Low-burden granulomas had increased abundance of T1-T17 subpopulation 1 ( $p=0.0324$ ,  
319 Kruskal Wallis with Dunn's multiple testing corrections), subpopulation 2 ( $p=0.0302$ ) and  
320 subpopulation 4 ( $p=0.0152$ ) compared to high-burden granulomas, suggesting a prominent role  
321 for both helper and cytotoxic functions of T1-T17 T cells (**Figure 4E, Table S8C**). However,  
322 there was a significant negative correlation only between T1-T17 subpopulations 2 and CFU  
323 (Spearman's rho  $-0.4482$ ,  $P=0.0216$ ), revealing an unexpected association of cytotoxic effectors  
324 in the control of Mtb. Surprisingly, T1-T17 subpopulation subpopulation 3 was not correlated  
325 with bacterial burden, despite expressing elevated levels of *IFNG* and *TNF* (**Figure 4E, Table**  
326 **S8C**), genes generally considered as critical to control Mtb infection (O'Garra et al., 2013;  
327 Scriba et al., 2017).

328

329 ***Additional cytotoxic features associated with bacterial control***

330 Additional T/NK cell subcluster correlates of control reinforce an association between  
331 cytotoxicity and bacterial burden (**Figure 3D, Table S8C**). Subcluster 4, constituting 3.8% of  
332 granuloma cells, is one of the six primary subclusters (1-6) defined broadly by cytotoxic  
333 features, such as expression of genes for granzymes (*GZMA*, *GZMB*, *GZMH*, *GZMK* and  
334 *GZMM*), granulysin (*GNLY*), or perforin (*PRF1*) (**Figure 3C**). Three of these subclusters  
335 (subclusters 1, 3, 4) are enriched for polyfunctional cytotoxic cells, characterized by the  
336 expression of multiple cytotoxic effector genes, while subclusters 2, 5 and 6 are distinguished by  
337 a more limited number of cytotoxic features.

338

339 Subcluster 4 is enriched for expression of *PRF1*, *GZMH*, *GZMB*, and *GZMM*, but not *GNLY*, a  
340 pattern consistent with that described for dicytotoxic CTLs (Balin et al., 2018) In addition, it is  
341 enriched for genes implicated in motility, migration and tissue residency, including *CX3CR1*,  
342 *TGFBR3*, and *S100A10*, and regulators of cell state such as *AHNAK*, *KLF3*, and *ZEB2* (**Figure**  
343 **3D-E; Table S7**). Further, subcluster 4 is enriched for expression of both *CD8A* and *CD8B*, and  
344 expresses *TCRA* and *TCRB* but not *TCRD* (**Figure 3B-C, Figure S5E-F**), suggesting that it is  
345 largely composed of conventional CD8 $\alpha\beta$  T cells (Fan and Rudensky, 2016). There are a small  
346 number of *CD4*-expressing cells in this subcluster which do not differ from the *CD8A* and *CD8B*-  
347 expressing cells in their expression of the subcluster defining genes (**Figure S5E-F**).  
348 Subcluster 4 is also enriched for expression of markers that can be expressed either by  
349 cytotoxic CD8 cells or NK cells, including *KLRD1*, *KLRF1*, *KLRK1* and *NKG7* (**Figure 3C**).

350

351 We sought to identify features that distinguished subcluster 4 from other subclusters that share  
352 cytotoxic features but are not associated with control. In contrast to subcluster 4, subcluster 1  
353 (4.3% granuloma cells, **Table S4C**), is characterized by high expression of all three classes of  
354 cytotoxic effectors genes—*GNLY*, *PRF1* and *GZMH*, *GZMA* *GZMB*—as well as *KLRD1*,  
355 *KLRC1*, *KLRC2*, *NKG7*, and shares some features with previously described tricytotoxic CD8+

356 cells (Balin et al., 2018). Subcluster 1 is enriched for the expression of *CD8A* but not *CD8B*, and  
357 has the highest proportion of TCRD expressing cells (**Figure 3B-C, Figure S5E-F, Table S8B**).  
358 Taken together, the data suggest that subcluster 1 contains a greater proportion of highly  
359 cytotoxic innate CD8+ T cells (possibly NKT cells),  $\gamma\delta$  T cells, and natural killer cells (NK) than  
360 subcluster 4. Subcluster 3, (0.4% of granuloma cells, **Table S4C**), which also does not  
361 correlate with control, appears to be more selectively enriched for NK cells as it is defined both  
362 by enrichment for cytotoxic and NK cell markers but also relatively low expression of *CD3D* and  
363 *CD3G* (**Figure 3C, Table S8BB**). Subcluster 5, representing 4.7% of granuloma cells,  
364 displays elevated expression of only a single cytotoxic marker, *GZMK*, which does not activate  
365 apoptotic caspases (Guo et al., 2010). Cytotoxic subcluster 6, meanwhile, is a very low  
366 abundance cluster (<0.3%) about which we cannot draw meaningful conclusions.

367  
368 The most revealing comparison was between subclusters 4 and 2 (1.9% of granuloma cells).  
369 Subcluster 2 is also enriched for NK and CD8 cell lineage marker expression such as *KLRC1*,  
370 *KLRB1*, *KLRG1*, *CD8A* and *TCRD* but is only moderately enriched for *PRF1* expression, and is  
371 not characterized by the expression of any other cytotoxic effector or cytokine genes (**Figure**  
372 **3B-C**). Interestingly, subcluster 2 is highly enriched for expression of activation markers *CD69*  
373 and *NR4A1* (Nur77) and for expression of *EGR1*, *EGR2* and *DUSP2*, a trio of transcription  
374 factors described to distinguish peripherally tolerant CD8 T cells in a model of tumor infiltrating  
375 lymphocytes (Schietinger et al., 2012). Strikingly, subcluster 2 is additionally defined by the  
376 expression of genes implicated in the inhibition of NF $\kappa$ B signaling, *NFKBIA* (I $\kappa$ B), *NFKBIZ* and  
377 *TNFAIP3*, but not markers suggestive of T cell exhaustion (**Figure 3C**). Taken together, these  
378 data suggest that cells in subcluster 2 are undergoing TCR activation but not undertaking  
379 effector functions and may be in an expression state suggestive of peripheral tolerance. The  
380 functional complexity of these subclusters, and the common and distinct responses they  
381 represent, supports a significant and underappreciated role for cytotoxic cells in TB granulomas

382 and suggests a need to further elucidate actionable avenues for plasticity for future preventions  
383 and cures.

384

### 385 ***Stem-like T cell function in TB lung granulomas***

386 Subcluster 7 (8.3% of granuloma cells, **Table S4C**) also correlates with control and is  
387 characterized by elevated expression of markers of naïve or memory CD4 and CD8 T cells  
388 including *TCF7*, *CCR7*, *IL7R*, and *TXNIP*, as well as genes associated with activation or  
389 memory state such as *CD69* and *ITGB1* (**Figure 3C-D**). These cells may represent a “stem-  
390 like” population of T cells, which are described as an early differentiating memory phenotype,  
391 distinct from naïve T cells, that are long-lived and possess a unique ability to proliferate and  
392 self-renew (Ahmed et al., 2016; Caccamo et al., 2018; Gattinoni et al., 2011). Similar cells have  
393 been reported in human and animal models of viral infection (Cartwright et al., 2016; Fuertes  
394 Marraco et al., 2015) and tumors (Ando et al., 2020; Brummelman et al., 2018; Wu et al., 2019),  
395 and in humans with Chagas disease (Mateus et al., 2015). In the tumor microenvironment,  
396 stem-like T cells have been described as expressing inhibitory receptors such as PD-1 (Siddiqui  
397 et al., 2019). This population is thought to undergo a proliferative burst after immune checkpoint  
398 blockade. By contrast, we do not identify enhanced expression of transcripts encoding  
399 inhibitory receptors in the stem-like subcluster (**Figure 3C**). Indeed, inhibitory receptor  
400 transcripts are only expressed highly on cells in subcluster 8 (1.2 % of granuloma cells), which  
401 appear to be regulatory T cells (Tregs) based on elevated expression of canonical Treg markers  
402 (*FOXP3*, *CTLA4*, *CGA*, *TIGIT*, *TNFRSF18*, *IL1RL1*, and *IKZF4*) (**Figure 3C**). The abundance of  
403 subcluster 8 neither positively nor negatively correlates with bacterial burden (**Figure 3D, Table**  
404 **S8B**).

405

### 406 ***Additional T/NK cell subclusters that correlate with control***

407 There were 3 additional T/NK subclusters that correlated with bacterial burden (**Figure 3D**,  
408 **Table S8B**). Subcluster 10 was a small *CD4* enriched subcluster (0.05%) defined by  
409 metallothionein genes such as *MT1* and *MT2* (**Figure 3C-D**); metallothionein-expressing T cells  
410 may play a role in negative regulation of Type 1 regulatory (Tr1) *CD4*<sup>+</sup> cells (Wu et al., 2013).  
411 Subcluster 11 was relatively abundant (2.4% of granuloma cells, **Table S4C**) and was  
412 characterized by expression of transcripts associated with cellular proliferation (*MKI67*, *STMN1*,  
413 and *TOP2A*) (**Figure 3C-D, Table S8B**), consistent with published data that T cell proliferation  
414 occurs within NHP and human granulomas (Gideon et al., 2015; McCaffrey et al., 2020; Ohtani,  
415 2013; Phuah et al., 2016; Phuah et al., 2012; Wong et al., 2018). Subcluster 12, representing  
416 0.6% of granuloma cells, is characterized by enrichment of genes associated with nuclear  
417 speckles and splicing factors such as *PNISR* and *SRRM2* (**Figure 3C**), the latter of which has  
418 been associated with alternate splicing in Parkinson disease (Shehadeh et al., 2010) and has a  
419 critical role in organization of 3D genome (Hu et al., 2019).

420

#### 421 ***T/NK cell subclusters that do not correlate with granuloma infection outcome***

422 There are 2 relatively abundant subclusters of lymphocytes that have gene expression profiles  
423 consistent with known cell types but which do not correlate with control, either positively or  
424 negatively (**Table S8B**). As noted above, one is subcluster 8, which displays elevated  
425 expression of canonical Treg markers (*FOXP3*, *CTLA4*, *CGA*, *TIGIT*, *TNFRSF18*, *IL1RL1*, and  
426 *IKZF4*) (Niedzielska et al., 2018; Zemmour et al., 2018) (**Figure 3C**) and *GATA3*, a Th2 lineage-  
427 defining transcription factor that has been observed in a subset of tissue-resident Tregs  
428 (Whibley et al., 2019). The second is subcluster 9, which is enriched for *CD4* expression and  
429 Type-I interferon inducible molecules (*MX1*, *ISG15*, *IFIT3*, *IFI6*, *IFIT1*, *RSAD2*, and *MX2*)  
430 (Szabo et al., 2019) and may represent activated *CD4*<sup>+</sup> T cells (**Figure 3C**). Despite  
431 expectations that activated *CD4*<sup>+</sup> T cells are critical mediators of TB control, the abundance of  
432 this population does not correlate with control at this time point.

433

434 ***Relationship between timing of granuloma formation and granuloma composition***

435 In this study, the time of granuloma appearance was tracked through serial PET-CT scans  
436 (Coleman et al., 2014b; Lin et al., 2013; Martin et al., 2017). In further examining the serial  
437 PET-CT scans for the four animals in the current study, we found that 15 of the granulomas  
438 randomly chosen for scRNA-seq were observed at 4 weeks p.i. (i.e., “early-detected”  
439 granulomas following Mtb infection), while another 11 were only seen at 10 weeks p.i. (i.e.,  
440 “late-detected” granulomas) (**Table S1**). Late-detected granulomas may be formed through  
441 dissemination (Martin et al., 2017); alternatively, some granulomas may take more time to reach  
442 the inflammatory threshold required to be identified by PET-CT scans (limit of detection  $\geq 1$ mm),  
443 potentially because of slower bacterial growth or more efficient immune control.

444

445 There was a striking difference (~40-fold) in granuloma-level bacterial burden (CFU) between  
446 early- (n=15, 3.6 log<sub>10</sub> CFU/granuloma, IQR: 3.2-4.6) and late-detected granulomas (n=11, 2  
447 log<sub>10</sub> CFU/granuloma, (0-2.8)) (p<0.0001) (**Figure 5A Table S10a**), although median size and  
448 granuloma FDG avidity were similar among all 26 at 10 weeks p.i. (**Table S1**). Critically, while  
449 there is a trend towards lower cumulative bacterial burden in late-detected lesions, the  
450 granuloma-level CEQ values were not significantly different between early- and late-detected  
451 granulomas (p=0.0737) (**Figure 5B, Table S10A**), suggesting that the lower bacterial burden  
452 (CFU) in new lesions was not strictly attributable to reduced bacterial growth. Moreover, the  
453 CFU/CEQ ratio (which is an inverse measure of bacterial killing) (Lin et al., 2014b) was ~10 fold  
454 lower in late-appearing granulomas (p=0.0107), indicating increased bacterial killing in those  
455 lesions. Comparison of cell-type proportions revealed that early- and late-detected granulomas  
456 were also characterized by differences in cellular composition. Many of the associations  
457 between cellular frequency and bacterial control were reflected in the differences between early  
458 and late lesions, including those with mast cells, plasma cells and the unified T/NK cell cluster,



459 as well as those with T/NK subclusters 13 (T1-T17) cells, 4 (cytotoxic) and 7 (stem-like T cells)  
460 (**Figure 5D-E**).

461

#### 462 ***Bacterial control in early detected granulomas is associated with cytotoxic function***

463 We sought to gain further insight into bacterial control specifically in the early appearing  
464 granulomas, which likely represent the original establishment of infection. We contrasted the  
465 early granulomas with the highest CFU (n=6, median CFU: 17,550,  $4.2\log_{10}$ ) and lowest CFU  
466 (n=6, median CFU: 2355,  $3.3\log_{10}$ ) ( $p=0.002$ , Mann-Whitney U) (**Figure 5F, Table S10**). In  
467 early-detected lesions with lower burden, there was again a significantly higher proportion of  
468 T/NK subclusters 4 ( $p=0.009$ , Mann-Whitney U) and 5 ( $p=0.004$ ), 7 (stem-like T cells) ( $p=0.041$ ),  
469 10 ( $p=0.004$ ) and subcluster 13 (T1-T17 cells) ( $p=0.041$ ) (Figure 5H). However, this analysis  
470 also revealed previously unappreciated associations between lower bacterial burden in early  
471 granulomas and additional subclusters of T/NK cells. These include the cytotoxic subclusters 1  
472 ( $p=0.041$ ) and 2 ( $p=0.002$ ) (**Figure 5H, Table S10**) and the T1-T17 subpopulation 3 marked by  
473 *IFNG* and *TNF* ( $p=0.026$ ) (**Table S5c, Table S10**). Taken together, these data suggest a  
474 prominent role for cytotoxic function and otherwise cryptic role for Type 1 cytokines, possibly  
475 from innate or early adaptive lymphocytes, in the initial control of Mtb infection.

476

#### 477 **TCR repertoires of TB lung granulomas**

478 Given the strong association between the abundance of specific T cell phenotypes and control  
479 of Mtb, we wondered whether these T cells might target common antigens (i.e., share common  
480 T cell receptors; TCRs). To investigate whether there was clonal enrichment among T cells, we  
481 reconstructed CDR3 sequences from granuloma T cells by performing targeted pulldowns of  $\alpha\beta$   
482 TCR sequences from the granuloma whole transcriptome amplification libraries to generate  
483 secondary sequencing libraries (**STAR\* Methods**) (Tu et al., 2019). Initially, we examined the  
484 extent of TCR- $\alpha$  and TCR- $\beta$  recovery and enrichment (i.e. CDR3- $\alpha$ ,  $n \geq 10$ ; CDR3- $\beta$  sequences,



485  $n \geq 12$ ; CDR- $\alpha\beta$ ,  $n \geq 10$ ) across the T and NK subclusters and observed enrichment of common  
486 CDR3 sequences in the T1-T17 and proliferating subclusters (13 and 11, respectively), as well  
487 as cytotoxic subclusters 4 and 5 (**Figure S6A-D, Table S9; STAR\* Methods**). Next, we  
488 examined sharing of enriched CDR3 sequences between granulomas. While we failed to  
489 observe public TCRs between animals (**Figure S6E**), within an animal (e.g., monkey 4017),  
490 there was substantial sharing of TCR- $\alpha$  and TCR- $\beta$  CDR3 sequences across lesions, including  
491 extensive sharing of CDR3 sequences between high-burden and low-burden granulomas  
492 (**Figure S6E**). This suggests that TCR enrichment is not strictly dependent on bacterial burden,  
493 and that antigens seen by enriched T cell clones may be similar in restrictive and permissive  
494 granulomas.

495  
496 We further investigated the relationship between CDR3 sequence, T cell phenotypes and  
497 granuloma-level CFU. We observed associations between CDR3 sequence and T/NK cell sub-  
498 cluster populations within enriched CDR3 sequences (**Figure S6F**). For example, we identified  
499 individual CDR3s where the majority of cells are derived from either the subcluster 13 (T1-T17)  
500 or 4 or 5 (cytotoxic). In cases where a single affinity receptor is associated with multiple  
501 subclusters, the two transcriptional phenotypes observed are typically T1-T17 and proliferating  
502 T cells (**Figure S6F**). In the animal with the broadest distribution of bacterial burdens among  
503 the randomly selected granulomas (monkey 4017), the enriched CDR3 sequences shared  
504 similar cellular phenotypes across high and low burden lesions (**Figure S6G, Table S14**).  
505 Taken together, these data do not support the hypothesis that T cell specificity defines bacterial  
506 control at the level of the granuloma.

507  
508 Finally, we leveraged targeted TCR reconstruction data to identify rare populations of donor-  
509 unrestricted T cells (DURTs; **STAR\* Methods**), which represent a heterogenous class of

510 invariant T cells, including mucosal associated invariant T (MAIT) cells, invariant natural killer T  
511 cells (iNKT cells), and CD1 restricted Germline-Encoded Mycolyl lipid reactive (GEM) T cells  
512 (Ogongo et al., 2020; Van Rhijn et al., 2015). Among DURT, we observe the highest  
513 frequency of T cells with the TRAV1-2/TRAJ33 MAIT-associated TCR combination (240/9,281  
514 (number of T cells with alpha recovery), 0.6% of total T cells), a population of iNKT cells  
515 (TRAV10-1/TRAJ18) TCR sequences (20/9,281, 0.05%) and GEM cells (TRAV1-2/TRAJ9)  
516 (5/9,281) (**Figure S6H**). Rather than defining a distinct phenotypic subset, we found that these  
517 cells distributed across several T and NK cell subclusters. Their low frequency precluded an  
518 accurate assessment of their relationship to granuloma-level bacterial burden.

### 519 ***Cellular ecology of pulmonary TB granulomas***

520 To assess whether specific cell types co-reside in TB lung granulomas more than would be  
521 expected by chance, we calculated the pairwise Pearson correlation matrix between all major  
522 cell types and sub-clusters across 26 granulomas (**Figure 6A; STAR\* Methods**). Using  
523 hierarchical clustering of this pairwise correlation matrix, we defined 5 primary groups of cell  
524 clusters/sub-clusters whose abundances are associated across granulomas (**Figure 6A, Table**  
525 **S11**). Of these, group 2 (“Red”), which includes mast cells, plasma cells and certain stromal  
526 populations, is significantly expanded in high-burden and early-detected lesions compared to  
527 low burden, late lesions. Group 4 (“Teal”), which primarily consists of T cell subclusters, is  
528 significantly higher in low burden and late-detected granulomas compared to high burden and  
529 early-detected granulomas (**Figure 6B, Table S12**).

530

531 Given the unexpected increased frequency and co-occurrence of plasma and mast cells in high  
532 burden granulomas, we looked for potential direct links between them (**Figure 6**). To  
533 understand diversity in plasma cell populations, we first examined the distribution of  
534 immunoglobulin heavy chain expression among the plasma cells and detected limited IgE  
535 expression. Instead, we observed that the vast majority of plasma cells express either *IGHA* or

536 *IGHG* constant chains (**Figure S8**), suggesting that they are the dominant antibody classes  
537 induced by Mtb in the granuloma microenvironment.

538

539 As the presence and function of mast cells in Mtb lung granulomas has yet to be characterized,  
540 we sought to further validate this transcriptional finding (**Figure 2C-D, Figure 6A-B**). To confirm  
541 the presence and examine the localization of mast cells in Mtb granulomas, we performed  
542 immunohistochemistry on paraffin embedded sections of NHP and human granulomas using  
543 Tryptase and C-kit/ CD117 markers by (**Figure 6C-D; STAR\* Methods**). This revealed that  
544 mast cells primarily localize to the outer regions of the granuloma, including the lymphocyte cuff  
545 in NHP (**Figure 6C**), and can be found within and around human granulomas (**Figure 6D**). In  
546 our data, mast cells are characterized by expression of *IL-13* (**Figure 6E**), which we also  
547 recently observed in a study of human nasal polyposis (Ordovas-Montanes et al., 2018) and *IL-*  
548 *4* (**Figure 6E**). Moreover, we find that mast cells co-occur with fibroblasts (**Figure 6A, Table**  
549 **S11**), consistent with a wound healing response (Rodrigues et al., 2019; Wong et al., 2020;  
550 Wulff and Wilgus, 2013). These data are consistent with a role for mast cells in peripheral  
551 fibrosis but might also suggest additional regulatory interactions with lymphocytes which will be  
552 the subject of future studies.

553 **Discussion**

554 A classic tenet in TB is that within most infected individuals the immune response is capable of  
555 controlling but never fully eliminating infection, and only a small percentage of infected  
556 individuals develop active disease (O'Garra et al., 2013). The cynomolgus macaque model of  
557 Mtb infection has taught us that the true picture is likely more complex. Within every individual,  
558 there are granulomas that represent geographically circumscribed instances of sterilizing  
559 immunity, of immune standoff—control but not sterilization—and, at least in some individuals,  
560 frank immune failure (Flynn, 2006, 2010; Lin et al., 2014b; Lin et al., 2009). This heterogeneity  
561 provides an opportunity to define cellular and molecular factors that correlate with bacterial  
562 control in the animal model that best recapitulates human infection and disease (Coleman et al.,  
563 2014a) to identify potential prevention and cure strategies for TB.

564

565 To enable unbiased investigation of which factors within a granuloma might facilitate bacterial  
566 control, we performed high-throughput single-cell transcriptional profiling of 26 granulomas  
567 spanning a wide range of bacterial burdens in cynomolgus macaques, while simultaneously  
568 tracking granuloma development by PET CT imaging and executing detailed microbiologic  
569 quantification. Our data represent the first unbiased single-cell investigation of factors  
570 associated dynamically with natural control of Mtb in granulomas. Here, we focused on  
571 granulomas at 10 weeks p.i., a key inflection point in Mtb infection where innate and adaptive  
572 immune responses are in place. In previous work, we demonstrated that in lesions formed upon  
573 infection, viable bacterial burdens are highest at ~4 weeks p.i. and that by ~10 weeks p.i.,  
574 bacterial burden decreases in many granulomas, with a subset having fully sterilized (Lin et al.,  
575 2014b) (**Figure S1**). As we can distinguish low bacterial burdens that occur through  
576 sterilization, rather than late or very slow bacterial growth, by measuring cumulative bacterial  
577 burden using a genome counting approach (CEQ), our imaging and microbiologic tools provide

578 a robust means of assessing lesional dynamics. This, in turn, allows us to capture features that  
579 associate with, and may be causally involved in, bacterial clearance (low CFU/CEQ).

580

581 Our single-cell analysis of granulomas at this pivotal 10 week p.i. time point revealed cellular  
582 factors correlated with both immune successes and failures. Consistent with previous  
583 observations, our findings reinforce a critical role for T cells in the control of Mtb infection.  
584 Nevertheless, given the substantial increase in resolution, our data paint a more nuanced  
585 picture, highlighting several subclusters and subpopulations within the larger unified T/NK cell  
586 cluster, including Type1-Type 17 hybrid subpopulations, cytotoxic cell subclusters, and stem-like  
587 memory T cells, that may play a critical role in bacterial control at the local granuloma level.  
588 What became clear through these analyses is that functional phenotypes, rather than canonical  
589 lymphocyte cell types, defined the subclusters and were associated with bacterial control,  
590 sometimes in a temporal fashion. Moreover, our data reveal several features associated with  
591 loss of bacterial control – most notably an increase in both mast and plasma cells in high burden  
592 lesions.

593

594 Although both CD4 and CD8 T cells have been implicated in control of Mtb infection, the  
595 cytotoxic function of lymphocytes in Mtb infection has been relatively understudied, with  
596 emphasis placed instead macrophage activating cytokines, such as IFN- $\gamma$  and TNF. However,  
597 subclustering the T/NK cluster revealed six subclusters that are defined by cytotoxic gene  
598 expression, each with a different flavor. This is the first study to describe the complexity of  
599 cytotoxic cells in granulomas in the context of bacterial burden. These subclusters did not align  
600 cleanly with canonical markers of cellular identity that would define them as classical CD8 $\alpha\beta$  or  
601 CD4 T cells, NK, NK T cells, or  $\gamma\delta$  T cells, but instead appear to be variable mixtures of cell  
602 types with common transcriptional programming. Of these, cytotoxic cluster 4, which is

603 enriched in CD8 $\alpha\beta$  T cells and defined by expression of several granzymes and perforin but  
604 only low levels of granulysin, is associated with control of Mtb in granulomas and likely  
605 represents cytotoxic effector T cells that target infected cells for apoptosis. Although the other  
606 cytotoxic subsets do not correlate with overall control of Mtb in granulomas, temporal analysis of  
607 granulomas via PET CT scanning allowed us to identify the early granulomas that form upon  
608 infection. In those granulomas, control of early Mtb infection was associated not only with  
609 cytotoxic subcluster 4 but also cytotoxic subclusters 1, 2, and 5. These include innate-like  
610 CD8+ subsets (NKT, NK, and  $\gamma\delta$  T cells) with tri-cytotoxic potential (perforin, granzymes, and  
611 granulysin) (subcluster 1), granzyme K expressing T cells (subcluster 5) and an interesting  
612 population with characteristics of peripheral tolerant T cells (subcluster 2). Subclustering the  
613 T1/17 cluster also revealed a cytotoxic T cell subpopulation that was associated with lower  
614 bacterial burdens. Together these data point to important and previously underestimated roles  
615 for cytotoxic innate and adaptive lymphocytes in temporal control of Mtb in granulomas, and  
616 support further study of cytotoxic cells as a potential target for vaccination.

617

618 The T1-T17 subcluster of the T and NK cell cluster, characterized by transcriptional patterns  
619 associated with both Type 1 and Type 17 T cells, was most strongly associated with overall  
620 bacterial control. While a number of studies have implicated lymphocytes with CD4 Th1 and  
621 Th17 functionality in the control of Mtb infection (Darrah et al., 2020; Gideon et al., 2015;  
622 Lyadova and Panteleev, 2015; Mpande et al., 2018), our scRNA-seq analysis reveals functional  
623 characteristics of cells associated with control that do not neatly follow expected T cell  
624 ontogenies defined by surface marker staining; rather, cells within express both Type 1 and  
625 Type 17 genes and are a mixture of *CD4* and *CD8* expressing T cells. While the T1-T17  
626 subcluster was defined by expression of several transcription factors and surface receptors  
627 consistent with Th17 cell differentiation, there was a paucity of expression of either *IL17A* or

628 *IL17F*. Although this could be due to failed detection or a difference between transcription and  
629 translation, we previously reported that lymphocytes expressing T1 or T17 cytokines were at  
630 relatively low frequencies in granulomas (Gideon et al., 2015). Notably, the T1-T17 subcluster  
631 shares many features with previously characterized T cell subsets including Th1\* and ex-Th17  
632 cells which do not express IL-17 (Acosta-Rodriguez et al., 2007; Basdeo et al., 2017). These  
633 subsets, observed previously among CD4 T cells, represent precursors to long lived tissue  
634 memory and have been shown to play a crucial protective role in autoimmunity, bacterial control  
635 and memory immune responses to pathogens (Amezcu Vesely et al., 2019; Liang et al., 2015;  
636 van Hamburg and Tas, 2018; Wacleche et al., 2016). Collectively, this suggests that the T1-  
637 T17 population represents a spectrum of tissue-resident effector and effector-memory T cells  
638 that arise in response to Mtb infection, and should be considered as targets to be exploited for  
639 vaccine development.

640  
641 The T1-T17 subcluster consists of both *CD4* and *CD8A/B* expressing cells with shared  
642 functional programming but contains subpopulations with unique features. The CD4-enriched  
643 subpopulation expresses some of the cluster defining genes associated with the stem-like T cell  
644 subcluster, but does not have obvious effector functions. Although exact phenotype of this  
645 subpopulation is not yet clear, there is a trend toward association with lower bacterial burden  
646 and could represent a T cell population restrained in effector functions and metabolic activity,  
647 preventing excessive activation which could lead to detrimental inflammation or exhaustion.  
648 The *CD8* T1-T17 subpopulation that associated with control was characterized by expression of  
649 cytotoxic effector molecules. Interestingly, most of the *IFNG* and *TNF* expression from the T1-  
650 T17 cluster came from a CD4 and CD8 subpopulation that did not associate with overall  
651 bacterial control except in early-detected granulomas. However, cytotoxic clusters 1, 2, 4 and 5  
652 also show some expression of *IFNG* and *TNF*, and cytotoxic cluster 4 is associated with overall  
653 bacterial control. The relatively limited association between expression of these

654 proinflammatory cytokines and bacterial control may reflect the temporal dynamics that  
655 distinguish lesions that have already achieved control versus those in which there is ongoing  
656 bacterial growth. In previous flow cytometry-based studies of NHP granulomas, expression of  
657 IFN- $\gamma$  did not correlate with bacterial burden, and other T1/T17 cytokines including TNF, IL-2  
658 and IL-17 only correlated with lower bacterial burden in conjunction with anti-inflammatory  
659 cytokines such as IL-10 expressed in the same granuloma.

660

661 Our data also revealed an interesting *CD4* and *CD8* expressing T cell cluster associated with  
662 control of bacterial burden that resembles stem-like T cells. We hypothesize that these cells  
663 may be a source of T cell renewal in granulomas, and may differentiate into the various  
664 functional subsets we observe within them. This hypothesis is supported by TCR sharing  
665 between the stem-like T cells and the T1/17 or other subclusters in a limited number of  
666 granulomas; more extensive TCR coverage will help to solidify this relationship in future studies.  
667 Another possibility is that the stem-like T cells represent memory T cells that are not specific for  
668 Mtb antigens, but migrate to the granuloma due to inflammatory signals, including chemokines.  
669 Indeed, flow cytometry based studies support that a majority of T cells in granulomas do not  
670 respond to Mtb antigens by making cytokines nor are they exhausted (Gideon et al., 2015;  
671 Sakai et al., 2016; Wong et al., 2018). The stem-like T cells warrant additional study, as they  
672 associate with control of Mtb in granulomas and could be explored as a potential vaccine target.

673

674 Importantly, to our knowledge, this study is the first to link longitudinal PET-CT imaging and  
675 single-cell sequencing data in the context of infectious disease, and this provides novel insights  
676 into the temporal evolution of immunologic control in Mtb infection. Interestingly, our imaging  
677 and microbiologic analyses revealed a significant relationship between the time at which  
678 granulomas are first observed on PET-CT and bacterial burden. Granulomas that are observed  
679 only on the 10-week scans had consistently lower bacterial burdens, despite having



680 approximately similar cumulative (CEQ) bacterial burdens. These data indicate that late-  
681 detected granulomas are not just captured at an earlier stage in their development as a result of  
682 dissemination or slower initial growth, but actually demonstrate greater bacterial killing.  
683 Focusing on the early-detected, or originally established, granulomas revealed that initial control  
684 of infection is significantly associated with cytotoxic functions (both innate and adaptative) as  
685 well as T1-T17 subpopulation 3 expressing *IFNG/TNF*. These findings solidfy the importance of  
686 considering cytotoxic function, not just cytokine function, in vaccine strategies that can prevent  
687 Mtb infection.

688

689 The T1-T17 subcluster was expanded primarily in late-detected relative to early-detected  
690 lesions and strongly associated with control of Mtb. We hypothesize that these granulomas  
691 arise in the context of a more established adaptive immune response and thus harbor a more  
692 bactericidal immune ecosystem. Such a model is consistent with recent observations that  
693 granulomas established in immune primed environments are better at killing Mtb than those  
694 established in a naïve lung – e.g., existing Mtb infection (Cadena et al., 2018) or IV-BCG or  
695 intrabronchial BCG vaccination, where Th1/17 expression patterns were observed to correlate  
696 with protection (Darrah et al., 2020; Dijkman et al., 2019). Here, we extend these findings by  
697 looking at primary infection within an unmanipulated system, linking imaging with scRNA-seq to  
698 identify the different paths granulomas may take based on when they arise, and the cells  
699 associated with these distinct outcomes. By examining the ecosystem of granulomas over time  
700 our data suggest that most T1/T17 cells emerge later in the infection and lead to increased  
701 killing of Mtb. Thus, targeting induction of these cells via vaccination could improve early control  
702 of infection.

703

704 The immune correlates of failure to control are even more unexpected. Although it has been  
705 hypothesized that immune exhaustion may contribute to failed bacterial control (Behar et al.,

706 2014; Jayaraman et al., 2016; Khan et al., 2017), we do not find associations between classical  
707 T cell exhaustion molecules and bacterial burden, which supports previous observations in NHP  
708 granulomas (Gideon et al., 2015; Sakai et al., 2016; Wong et al., 2018). Instead, lesions with  
709 high bacterial burdens are characterized by significantly higher proportions of plasma and mast  
710 cells than those with lower burdens. Notably, while these plasma cells do not appear to be  
711 expressing *IgE* (in contrast to *IGHA* and *IGHG*), the mast cells express *IL-13* and *IL-4*,  
712 suggesting a possible link between the pair (Takeuchi et al., 2015). The expression of *IGHA*  
713 and *IGHG* and presence of plasma cells in granulomas support the notion that antibodies may  
714 play a prominent role in Mtb infection, perhaps with different effects as a function of antibody  
715 quality (Achkar et al., 2015; Jacobs et al., 2016; Lu et al., 2016). Immunohistochemistry  
716 confirms the presence of mast cells in TB granulomas in both NHP and humans, where they  
717 appear located in and around the lymphocyte cuff, suggesting potential regulatory interactions  
718 with T and NK cells or with the macrophages present within this region. *IL-13* and *IL-4* or  
719 expression of *IL-4R $\alpha$*  (the receptor for these cytokines) have been reported to modulate CD8 T  
720 cell function, including inhibition of cytotoxic activity, supporting the potential for mast cells to  
721 regulate the T cell responses in granulomas (Kienzle et al., 2005; Wijesundara et al., 2013).  
722 While mast cells have been described in granulomatous conditions, such as TB lymphadenitis  
723 (Taweevisit and Poumsuk, 2007), leprosy skin lesions (Bagwan et al., 2004), and liver  
724 granulomas (Celasun et al., 1992), and may orchestrate immune cross talk in TB (Garcia-  
725 Rodriguez et al., 2017), this is the first description of direct correlation with Mtb bacterial burden  
726 in individual TB granulomas. While more detailed studies on the roles of mast cells in TB are  
727 indicated, this observation provides exciting new avenues to explore the immune architecture of  
728 failed immunity in TB lung granulomas, and suggests new intervention strategies. In  
729 conjunction with elevated mast and plasma cell frequencies, we also observed higher  
730 proportions of fibroblasts in high burden lesions. This may reflect attempts at wound healing  
731 (i.e., a canonical type-2 response) in the face of higher bacterial burden, as suggested by other

732 studies (Wong et al., 2020) and uncovers potentially therapeutically relevant intercellular  
733 interactions (Rubinchik and Levi-Schaffer, 1994) for future follow up.

734

735 It is important to recognize the limitations in our data. Our TCR sequencing data reveal  
736 significant sharing of TCR sequences between granulomas within, but not across, animals. T  
737 cells appear to be responding to similar antigens across granulomas, irrespective of bacterial  
738 burden, suggesting that the abundance and composition of T cell phenotypes, rather than  
739 antigen specificity, is a critical determinant of granuloma-level bacterial control. However, our  
740 recovery of CDR3 sequences was relatively low, which limits our ability at this time to go beyond  
741 analysis of enriched clones.

742

743 Moreover, the granuloma is an inherently heterogenous environment and includes necrotic  
744 debris, requiring robust technical correction and quality control; this results in an analysis of only  
745 high-quality cells. Since only a fraction of cells from each granuloma are analyzed, proportions  
746 may not reflect the true composition of cells within a granuloma and may be skewed toward  
747 lymphocytes highlighting the importance of orthogonal validations. Given cell and granuloma  
748 numbers, rare populations, including DURT, were more difficult to analyze in detail. We  
749 focused primarily on cell types, subclusters, and subpopulations that were correlated with  
750 bacterial burden in granulomas. While macrophages are clearly an important component of the  
751 immune response in TB granulomas, the heterogeneity of the myeloid populations requires  
752 further in depth evaluation with additional samples and time points to appreciate which functions  
753 and cell types are associated with control or failure. Relatedly, the granuloma landscape  
754 investigated here is from a single, albeit pivotal, time point. It is likely that expression of certain  
755 genes that occur early in infection and then are downregulated as infection progresses will be  
756 missed, as will some populations critical to guiding overall lesional outcome. More generally,  
757 matched analyses of earlier and later time points post-infection along with analysis of lung

758 tissue and granulomas from vaccinated or reinfected and protected animals will provide a more  
759 complete picture of the temporal control of Mtb in granulomas.

760

761 In summary, our study affords unprecedented, unbiased views of the cellular and molecular  
762 features associated with control of Mtb in primary lung granulomas. Beyond recapitulating  
763 canonical correlates, our analysis defines nuanced actionable innate and adaptive functional  
764 cell states including novel data on cytotoxic subsets, stem-like T cells and T1/17 CD4 and CD8  
765 T cells, uncovers a permissive role for cells consistent with type-2 responses (mast and plasma  
766 cells) and sheds light on essential dynamics among host-pathogen interactions (Iwasaki and  
767 Medzhitov, 2015). Collectively, our data substantiate a model where Mtb burden within early  
768 forming lesions is dictated by the interplay among restrictive, inflammatory innate-like responses  
769 and permissive, protective type-2 (wound healing) responses seeking to balance bacterial  
770 control with the maintenance of essential tissue functionality, respectively. In those lesions  
771 forming late, this balance can be tipped by an onslaught of adaptive T1-T17 and cytotoxic  
772 responses which are capable of controlling local disease, given sufficient access. Such a  
773 framework is consistent with previous observations of natural (Cadena et al., 2018) or induced  
774 (Darrah et al., 2020) control, and nominates several discrete putative axes of intra- and  
775 intercellular signaling that may prove therapeutically or prophylactically valuable, as well as  
776 intellectual links to other inflammatory and infectious diseases that affect epithelial barrier  
777 tissues.

778

779 **ACKNOWLEDGEMENTS**

780 We are grateful to the research and veterinary technicians: Chelsea Chedrick, Carolyn Bigbee,  
781 Nicholas Schindler, Mark Rogers, Tara Rutledge, Chelsea Causgrove and Brianne Stein in the  
782 Flynn lab who assisted with this work, as well as helpful discussions with members of the Flynn,  
783 Scanga, Mattila, Lin and Shalek laboratories. We also thank the efforts of the University of  
784 Pittsburgh Division of Laboratory Animal Research technicians for husbandry of the animals.  
785 This work was supported in part by the Searle Scholars Program (AKS), the Beckman Young  
786 Investigator Program (AKS), a Sloan Fellowship in Chemistry (AKS), the NIH (5U24AI118672,  
787 BAA-NIAID-NIHAI201700104) (AKS), and the Bill and Melinda Gates Foundation (OP1139972:  
788 AL, SMB, SMF, JLF, AKS). We acknowledge support from the American Lung Association  
789 RG571577(HPG), F30-AI143160 (TKH), NIH T32A1065380 (NLG), NSF GRFP grant (SKN  
790 1122374) Wellcome Trust Fellowship award 210662/Z/16/Z (AL), Koch Institute Support (core)  
791 grant P30-CA14051 from the National Cancer Institute (CL), NIH CFAR P30 AI060354(BB) NIH  
792 R01A1022553 (BB), JR (T32 A1007387).

793

794 **DECLARATION OF INTEREST**

795 **A.K.S.** reports compensation for consulting and/or SAB membership from Merck, Honeycomb  
796 Biotechnologies, Cellarity, Cogen Therapeutics, Ochre Bio, and Dahlia Biosciences.  
797 **CL:** shareholder and consultant Honeycomb biotechnologies.

798 **Figures legends:**

799

800 **Figure 1. Study design, experimental set up, characteristics of animals over the course of**  
801 **Mtb infection and granuloma bacterial burden.**

- 802 **A.** Architecture of macaque TB lung granuloma, where lymphocytes and macrophages are  
803 present in distinct regions. Immunohistochemistry and confocal microscopy were  
804 performed on a granuloma from an animal at 11 weeks post-Mtb infection to visualize  
805 localization of CD11c+ macrophages (cyan), CD3+ T cells (yellow), and CD20+ B cells  
806 (magenta).
- 807 **B.** Study design: Cynomolgus macaques (n=4) were infected with a low-dose inoculum of  
808 Mtb (Erdman strain) and serial PET-CT scans were performed at 4, 8, and 10 weeks  
809 post-infection with the final scan used as a map for lesion identification at necropsy.  
810 Individual granulomas were excised and homogenized. CFU and CEQ assays were  
811 performed on all granulomas (top right) and 26 individual granulomas across 4 animals  
812 were randomly selected at necropsy for Seq-Well assays (bottom right).
- 813 **C.** Total lung FDG activity (in log scale) measured by PET scans of each animal at 4, 8 and  
814 10-weeks post-Mtb infection showing trajectories of lung inflammation.
- 815 **D.** Distribution of CFU per granuloma sampled for Seq-Well assay for each animal. Each  
816 dot is an individual granuloma.
- 817 **E.** CFU log<sub>10</sub> per granuloma (total live bacteria) organized by tertiles. Each dot is a  
818 granuloma. Colors correspond to CFU tertile ranges in E-G: Green: 0-500 CFU, Yellow:  
819 500-5000 CFU, and Red: >5000 CFU. Box plot showing median, IQR and range. Kruskal  
820 Wallis test with Dunn's multiple testing correction for panels E-G.
- 821 **F.** CEQ log<sub>10</sub> per granuloma (Chromosomal equivalents, CEQ, live + dead Mtb) organized  
822 by tertiles. Colors correspond to CFU tertile ranges.
- 823 **G.** Ratio between CFU (viable bacteria) and CEQ (total bacterial burden) i.e., relative  
824 bacterial survival. Lower ratio (negative values) corresponds to increased killing and  
825 higher ratio corresponds to increased Mtb survival.

826

827 **Figure 2. Analysis of single-cell sequencing of tuberculosis lung granulomas.**

- 828 **A.** UMAP plot of 109,584 cells from 26 granulomas colored by identities of 13 generic cell  
829 types.

- 830 B. Expression levels of cluster defining genes enriched across 13 generic cell types. Color  
831 intensity corresponds to the level of gene expression, while the size of dots represents  
832 the percent of cells with non-zero expression in each cluster.
- 833 C. Significant correlations between proportion of T/NK cells, mast cells, plasma cells and  
834 fibroblasts with bacterial burden of individual granulomas (CFU per granuloma) using  
835 non-parametric Spearman's rho correlation test.
- 836 D. Relationship between granuloma proportional composition of cell type clusters and CFU  
837 in tertiles. Statistics: Kruskal Wallis test with Dunn's multiple testing correction. Adjusted  
838 p value for cell type composition comparing low and high tertiles is presented in boxes.  
839 Box plot showing median, IQR and range; each dot represents a granuloma.  
840 Spearman's Rho and p values are shown in boxes at the top for corresponding cell type  
841 clusters.

842

843 **Figure 3: Diversity in the unified T and NK cell cluster and relationship to granuloma-**  
844 **level bacterial burden.**

- 845 A. Subclustering 41,222 cells in the unified T/NK cell cluster, colored by subclusters.  
846 Subclusters are numbered based the expression patterns.
- 847 B. Frequency of expression of TCR genes *TRAC*, *TRBC1* or *TRBC2* (yellow) and *TRDC*  
848 (green) across 13 T/NK cell subclusters.
- 849 C. Expression levels of T/NK cell cluster-defining genes. Color intensity corresponds to the  
850 level of gene expression and the size of dots represents the percent of cells with non-  
851 zero expression in each cluster. Y-axis identifies subclusters.
- 852 D. Correlations between proportion of T/NK cells and subclusters (1-13) with bacterial  
853 burden of individual granulomas (CFU per granuloma) using non-parametric Spearman's  
854 rho correlation test. Subclusters with significant negative correlation values are  
855 highlighted in blue.

856

857 **Figure 4: Phenotypic Diversity in T1-T17 cells.**

- 858 **A.** T1-T17 subcluster overlaid on unified T/NK cell cluster (left) and colored by normalized  
859 expression values for T1-T17 subcluster-defining genes (bold outlined boxes) and non-  
860 enriched canonical Type1 and Type 17 genes (right).
- 861 **B.** Subclustering of 9,234 T1-T17 cells resulting in 4 phenotypic sub-populations.

- 862 **C.** Cluster defining genes for T1-T17 subpopulation 1, 2, 3 and 4. Color intensity corresponds  
863 to the level of gene expression and the size of dots represents the percent of cells with non-  
864 zero expression in each cluster.
- 865 **D.** Subclustering of T1-T17 cells colored by normalized gene expression values for selected  
866 subcluster (top row) and sub-population defining genes.
- 867 **E. Left:** Relationship between the T1-T17 sub-populations and granuloma bacterial burden in  
868 tertiles. Statistics: Kruskal Wallis test with Dunn's multiple testing correction. Adjusted p  
869 value for cell type composition comparing low and high CFU tertiles is in boxes. Box plot  
870 showing median, IQR and range; each dot represents a granuloma. **Right:** Correlations  
871 between proportion T1-T17 subcluster and subpopulation 1-3 with bacterial burden of  
872 individual granulomas (CFU per granuloma) using non-parametric Spearman's rho  
873 correlation test.

874

#### 875 **Figure 5. Association of cell type proportions with timing of granuloma formation**

- 876 **A-C.** CFU  $\log_{10}$  values(A), CEQ  $\log_{10}$  values (B) and relative bacterial survival (CFU/CEQ)(C) for  
877 granulomas grouped by time of initial observation by PET-CT imaging. Early detection  
878 (yellow): those identified at 4 weeks p.i.; Late detection (green): those identified at 10  
879 week p.i..
- 880 **D,E.** Canonical cell type clusters (D) and T/NK subclusters (E) that are significantly different  
881 between early and late detection granulomas. See Table S10 for full data.
- 882 **F.** Early (4 week) detection granulomas comparing lowest CFU (n=6) and highest CFU (n=6)  
883 granulomas.
- 884 **G, H.** Relationship between the abundance of canonical cell types (G) and T/NK subclusters (H)  
885 with bacterial burdens among low CFU and high CFU early-detected granulomas. Each  
886 dot represents a granuloma. Box plot shows median, IQR and range. Statistics: non-  
887 parametric Mann Whitney U test. See Table S10 for full data

888

#### 889 **Figure 6: Cellular ecosystem in TB lung granulomas**

- 890 **A.** Pairwise Pearson correlation values proportions of canonical cell types and T/NK and  
891 macrophage subclusters across 26 granulomas. Hierarchical clustering of correlation  
892 coefficients identified 5 groups (indicated by color) of cell types with correlated  
893 abundance in granulomas.
- 894 **B.** Relationship between the distribution of correlated cell-types between high and low CFU  
895 granulomas (left), and across all 26 granulomas ordered from lowest CFU (left) to



896 highest CFU (right). Colored boxes indicate granuloma CFU range by green boxes (low),  
897 orange boxes (mid) and maroon boxes (high); which granulomas came from which  
898 animal by salmon boxes (3817), yellow boxes (3917), Navy blue boxes (4017) and 4217  
899 boxes (light blue) and time of detection is indicated by yellow boxes (10 weeks) and  
900 green boxes (4 weeks).

901 **C.** Detection of mast cells in a 10-week NHP granuloma using immunohistochemistry,  
902 staining for tryptase (green) and c-kit (CD117)(red).

903 **D.** Detection of mast cells in a human lung granuloma. Hematoxylin and eosin stain and  
904 immunohistochemistry with multinucleated giant cells (stars, (top left) and c-kit (CD117)  
905 staining (indicated by arrows, top and bottom right).

906 **E. Left:** UMAP plot of 109,584 cells from 26 granulomas colored by identities of 13 generic  
907 cell types. **Right:** expression levels of IL-13 and IL-4 genes overlaid on UMAP plot of  
908 109,584 cells.

909

#### 910 **Supplemental figures:**

#### 911 **Figure S1: CFU per granuloma decreases over time.**

912

913 **A.** Each column depicts the CFU for all granulomas of an individual macaque (N=88  
914 macaques), ranging from 4 weeks to 17 weeks post-infection. Each dot represents a  
915 granuloma. Lines are at means (per animal) and different colors represent weeks post-  
916 infection.

917 **B.** CFU per granuloma decreases significantly starting at 10-11 weeks post-infection. Each  
918 dot represents the mean CFU per granuloma of an individual animal, with the x-axis  
919 indicating weeks post-infection at which necropsy was performed. Lines are at  
920 medians. Differences between time points were tested using Kruskal-Wallis test with  
921 Dunn's multiple comparison adjustment. (\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p <$   
922  $0.0001$ .)

923

#### 924 **Figure S2: Sequencing, alignment and QC pipeline (see STAR\* methods)**

925 **A, D, I.** Array-specific processing pipeline.

926 **B.** Array specific Louvain clustering (Resolution = 1.25).

927 **C.** Cluster-defining gene expression was determined within each array.

928 **E.** Overview of Cluster-Specific Summary Score.

- 929 **F.** Estimation of soup-thresholds for correction of ambient RNA contamination. Left:  
930 Relationship between soup-thresholds (x-axis) the number of soup defining genes  
931 detected for each array (y-axis). Right: Relationship between soup-thresholds (x-axis)  
932 and the cumulative proportion of soup-defining gene expression (y-axis).  
933 **G.** Hierarchical clustering results used to identify and remove clusters defined by  
934 ambient contamination from each array.  
935 **H.** t-SNE plot showing removal of clusters characterized as ambient RNA.  
936 **J.** Estimation of array-specific contamination rates using SoupX.  
937 **K.** Identification and removal of array-specific doublets.  
938

939 **Figure S3: Identification of Canonical Cell Types.**

- 940 **A.** Waterfall plot showing stability of cell-type clusters at multiple clustering resolutions.  
941 Boxed row (resolution=1.00) selected for downstream analysis.  
942 **B, C** Distribution of lung cell-type signatures obtained from the Tabula muris (B) and Mouse  
943 cell (C) atlas.  
944 **D.** UMAP plot of 109,584 cells colored by Louvain clusters (resolution = 1.00).  
945 **F.** Waterfall plot showing the stability of sub-clustering analysis of 3,123 cells with a  
946 proliferating gene signature.  
947 **G.** Distribution of canonical cell type signatures across subclusters of proliferating cells.  
948 **H.** UMAP plot of 109,584 cells colored by 13 canonical cell type clusters.  
949 **I.** Expression levels of cluster-defining genes overlaid on UMAP plot in panel G.  
950 **J.** Correlations between bacterial burden and abundance of each canonical cell type  
951 cluster. Correlation was calculated using non-parametric Spearman's rho test.  
952

953 **Figure S4. Macrophage heterogeneity in Mtb granulomas.**

- 954 **A.** Waterfall plot showing the stability of macrophage sub-clusters. Boxed row  
955 (resolution=0.55) selected for downstream analysis.  
956 **B.** UMAP plot of 27,670 macrophage cluster colored by phenotypes.  
957 **C.** Cluster-defining genes across macrophage subclusters.  
958 **D.** Macrophage subcluster-defining genes overlaid on macrophage plot in panel B.  
959 **E.** Boxplots showing bacterial burden in tertiles and composition of macrophage sub-  
960 populations. Box plot showing median, IQR and range; each dot represents a  
961 granuloma. Kruskal Wallis test with Dunn's multiple testing correction. The only  
962 significant value is for Macrophage subcluster 3 between low and high CFU tertiles

963 p=0.0004). Spearman's Rho and p values are shown in boxes at the top for  
964 corresponding macrophage subclusters.

965

### 966 **Figure S5. Sub-clustering and phenotypic identification of T/NK cell populations**

967

- 968 **A.** Waterfall plot showing the stability of T/NK cell sub-clustering. Boxed row  
969 (resolution=0.55) selected for downstream analysis.
- 970 **B.** UMAP plot of 44,766 T/NK cells with a sub-cluster of 3,544 T/NK cells defined by  
971 residual contamination highlighted (blue).
- 972 **C.** Waterfall plot showing the stability of T/NK cell sub-clustering following removal of  
973 contaminated T cell sub-cluster. Boxed row (resolution=0.75) selected for downstream  
974 analysis.
- 975 **D.** T/NK subclustering UMAP overlaid with normalized gene expression for CD4, CD8A,  
976 and CD8B (top). Expression of these genes across 13 sub-clusters (bottom) where color  
977 intensity corresponds to level of gene expression and size of dots represents the percent  
978 of cells with non-zero expression in each cluster.
- 979 **E.** Frequency of expression of *CD4* (blue), *CD8A* and/ *CD8B* (green), *CD4* and *CD8A/B*  
980 (orange) or no expression of *CD4/CD8A/B* (yellow) across 13 T/NK cell subclusters.
- 981 **F.** UMAP plots overlaid with normalized expression levels for selected T/NK cell subcluster-  
982 defining genes.

983

### 984 **Figure S6: TCR repertoires in granulomas**

- 985 **A.** UMAP plots of 41,222 T/NK cells colored by recovery of TCR CDR3 sequences
- 986 **B.** Fraction of each T/NK sub-cluster with recovery of TCR CDR3 sequences
- 987 **C.** Enrichment of TCR-alpha (Alpha-CDR3  $\geq 10$  cells, left), TCR-beta (Beta-CDR3  $\geq 12$   
988 cells, middle), and both TCR-alpha and TCR-beta (Alpha-Beta-CDR3  $\geq 12$  cells, right)  
989 in the unified T/NK cluster.
- 990 **D.** Fraction of each T/NK sub-cluster enriched for TCR-alpha (red), TCR-beta (blue), and  
991 TCR-alpha and TCR-beta (green) sequences.
- 992 **E.** Sharing of enriched TCR sequences across all granulomas. Colors above heatmaps  
993 correspond to animal and CFU tertiles. Individual heatmaps are shown for TCR-alpha  
994 (Alpha-CDR3  $\geq 10$  cells, left), TCR-beta (Beta-CDR3  $\geq 12$  cells, middle), and TCR-  
995 Alpha/Beta (Alpha-Beta CDR3  $\geq 10$  cells, right).

996 **F.** Distribution of T/NK cell subclusters within enriched alpha-beta TCR clones across all  
997 animals.

998 **G.** Distribution of T/NK cell subclusters within enriched alpha-beta TCR clones between  
999 high and low burden lesions within Animal 4017.

1000 **H.** UMAP plots of 41,222 T/NK cells colored by detection of TRAJ TRAV TCR sequences  
1001 (MAIT: genes , iNKT (genes), and GEM (genes)).

1002

1003 **Figure S7 Late detection granulomas have lower CFU than early detection granulomas.**

1004 **A.** CFU per granuloma is shown for early detection (blue) and late detection (red) within  
1005 each animal. Box plots lines represent the median, IQR and range Each dot represents  
1006 a granuloma.

1007 **B.** CFU is significantly lower in new granulomas within animals. Each dot (and line)  
1008 represents the median CFU per granuloma of each animal. Statistics: paired t-test .

1009

1010 **Figure S8. Expression of selected functional transcripts.**

1011 **A.** Expression levels of select functional genes overlaid on UMAP plot of 109,584 cells.

1012 **B.** UMAP plot of 109,584 cells from 26 granulomas colored by identities of 13 generic cell  
1013 types.

1014

1015

1016

1017

1018

1019 **Supplemental Table legends:**

1020 **Table S1:** Granuloma CFU, CEQ , CFU/CEQ; PET-CT: SUV-R, Size and Time of detection

1021 **Table S2a:** Seq-Well array loading densities and doublet rate

1022 **Table S2b:** Technical correction data: SoupX

1023 **Table S2c:** Doublet removal Metadata

1024 **Table S2d:** Cell level metadata

1025 **Tablet S3:** Canonical cell type enrichment gene list: 13 cell type clusters

1026 **Table S4:** Cells type composition: percentage of assigned granuloma cells. A) canonical cell  
1027 type clusters, b)macrophage subclusters, c) T/NK subclusters and d) T1T17 subpopulation

1028 **Tablet S5:**Macrophage subcluster enrichment:9 subclusters

1029 **Table S6:** T/NK subclustering: enrichment gene list :13 T/NK subclusters

1030 **Table S7:**Type1-Type-17 subpopulation enrichment

1031 **Table S8:** Correlation (Spearman's rho) with bacterial burden and difference between in  
1032 percentage of cells between low and high CFU tertiles (Kruskal-Wallis Test with Dunn's  
1033 multiple testing correction): A) canonical cell type clusters, b) T/NK subclusters and C) T1T17  
1034 subpopulation

1035 **Table S9:** TCR repertoires

1036 **Table S10:** Difference in cellular abundance and association with bacterial burden. (a) Early  
1037 detection and late detection granulomas, (b)Early detection granulomas

1038 **Table S11:** Cellular ecology

1039 **Table S12:** Association of cell group abundance with bacterial burden : (1) All: CFU low vs  
1040 high, (2) Early detection: CFU: lowest vs highest and timing of granuloma detection (Early vs  
1041 late).

1042 **References:**

- 1043 Achkar, J.M., Chan, J., and Casadevall, A. (2015). B cells and antibodies in the defense  
1044 against *Mycobacterium tuberculosis* infection. *Immunol Rev* 264, 167-181.
- 1045 Acosta-Rodriguez, E.V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M.,  
1046 Lanzavecchia, A., Sallusto, F., and Napolitani, G. (2007). Surface phenotype and  
1047 antigenic specificity of human interleukin 17-producing T helper memory cells. *Nat*  
1048 *Immunol* 8, 639-646.
- 1049 Ahmed, R., Roger, L., Costa Del Amo, P., Miners, K.L., Jones, R.E., Boelen, L., Fali, T.,  
1050 Elemans, M., Zhang, Y., Appay, V., *et al.* (2016). Human Stem Cell-like Memory T Cells  
1051 Are Maintained in a State of Dynamic Flux. *Cell Rep* 17, 2811-2818.
- 1052 Algood, H.M., Lin, P.L., and Flynn, J.L. (2005). Tumor necrosis factor and chemokine  
1053 interactions in the formation and maintenance of granulomas in tuberculosis. *Clin Infect*  
1054 *Dis* 41 Suppl 3, S189-193.
- 1055 Amezcua Vesely, M.C., Pallis, P., Bielecki, P., Low, J.S., Zhao, J., Harman, C.C.D.,  
1056 Kroehling, L., Jackson, R., Bailis, W., Licona-Limon, P., *et al.* (2019). Effector TH17  
1057 Cells Give Rise to Long-Lived TRM Cells that Are Essential for an Immediate Response  
1058 against Bacterial Infection. *Cell* 178, 1176-1188 e1115.
- 1059 Ando, M., Ito, M., Srirat, T., Kondo, T., and Yoshimura, A. (2020). Memory T cell,  
1060 exhaustion, and tumor immunity. *Immunol Med* 43, 1-9.
- 1061 Ardain, A., Domingo-Gonzalez, R., Das, S., Kazer, S.W., Howard, N.C., Singh, A.,  
1062 Ahmed, M., Nhamoyebonde, S., Rangel-Moreno, J., Ogongo, P., *et al.* (2019). Group 3  
1063 innate lymphoid cells mediate early protective immunity against tuberculosis. *Nature*  
1064 570, 528-532.
- 1065 Arora, P., Foster, E.L., and Porcelli, S.A. (2013). CD1d and natural killer T cells in  
1066 immunity to *Mycobacterium tuberculosis*. *Adv Exp Med Biol* 783, 199-223.
- 1067 Bagwan, I.N., Khandekar, M.M., Kadam, P., Jadhav, M.V., and Deshmukh, S.D. (2004).  
1068 A study of mast cells in granulomatous lesions of skin, with special emphasis on  
1069 leprosy. *Indian J Lepr* 76, 31-37.
- 1070 Balin, S.J., Pellegrini, M., Klechevsky, E., Won, S.T., Weiss, D.I., Choi, A.W., Hakimian,  
1071 J., Lu, J., Ochoa, M.T., Bloom, B.R., *et al.* (2018). Human antimicrobial cytotoxic T  
1072 lymphocytes, defined by NK receptors and antimicrobial proteins, kill intracellular  
1073 bacteria. *Sci Immunol* 3.
- 1074 Basdeo, S.A., Cluxton, D., Sulaimani, J., Moran, B., Canavan, M., Orr, C., Veale, D.J.,  
1075 Fearon, U., and Fletcher, J.M. (2017). Ex-Th17 (Nonclassical Th1) Cells Are  
1076 Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by  
1077 Regulatory T Cells. *J Immunol* 198, 2249-2259.

- 1078 Behar, S.M., Carpenter, S.M., Booty, M.G., Barber, D.L., and Jayaraman, P. (2014).  
1079 Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis  
1080 infection: immunity interruptus. *Semin Immunol* 26, 559-577.
- 1081 Brummelman, J., Mazza, E.M.C., Alvisi, G., Colombo, F.S., Grilli, A., Mikulak, J.,  
1082 Mavilio, D., Alloisio, M., Ferrari, F., Lopci, E., *et al.* (2018). High-dimensional single cell  
1083 analysis identifies stem-like cytotoxic CD8(+) T cells infiltrating human tumors. *J Exp*  
1084 *Med* 215, 2520-2535.
- 1085 Burel, J.G., Lindestam Arlehamn, C.S., Khan, N., Seumois, G., Greenbaum, J.A.,  
1086 Taplitz, R., Gilman, R.H., Saito, M., Vijayanand, P., Sette, A., *et al.* (2018).  
1087 Transcriptomic Analysis of CD4(+) T Cells Reveals Novel Immune Signatures of Latent  
1088 Tuberculosis. *J Immunol* 200, 3283-3290.
- 1089 Caccamo, N., Joosten, S.A., Ottenhoff, T.H.M., and Dieli, F. (2018). Atypical Human  
1090 Effector/Memory CD4(+) T Cells With a Naive-Like Phenotype. *Front Immunol* 9, 2832.
- 1091 Cadena, A.M., Flynn, J.L., and Fortune, S.M. (2016). The Importance of First  
1092 Impressions: Early Events in Mycobacterium tuberculosis Infection Influence Outcome.  
1093 *mBio* 7, e00342-00316.
- 1094 Cadena, A.M., Hopkins, F.F., Maiello, P., Carey, A.F., Wong, E.A., Martin, C.J., Gideon,  
1095 H.P., DiFazio, R.M., Andersen, P., Lin, P.L., *et al.* (2018). Concurrent infection with  
1096 Mycobacterium tuberculosis confers robust protection against secondary infection in  
1097 macaques. *PLoS Pathog* 14, e1007305.
- 1098 Canetti, G. (1955). The tubercle bacillus in the pulmonary lesion of man:  
1099 histobacteriology and its bearing on the therapy of pulmonary tuberculosis. Springer.
- 1100 Cartwright, E.K., Palesch, D., Mavigner, M., Paiardini, M., Chahroudi, A., and Silvestri,  
1101 G. (2016). Initiation of Antiretroviral Therapy Restores CD4+ T Memory Stem Cell  
1102 Homeostasis in Simian Immunodeficiency Virus-Infected Macaques. *J Virol* 90, 6699-  
1103 6708.
- 1104 Celasun, B., Crow, J., and Scheuer, P.J. (1992). Mast cells in granulomatous liver  
1105 disease. *Pathol Res Pract* 188, 97-100.
- 1106 Chackerian, A., Alt, J., Perera, V., and Behar, S.M. (2002). Activation of NKT cells  
1107 protects mice from tuberculosis. *Infect Immun* 70, 6302-6309.
- 1108 Chancellor, A., White, A., Tocheva, A.S., Fenn, J.R., Dennis, M., Tezera, L., Singhania,  
1109 A., Elliott, T., Tebruegge, M., Elkington, P., *et al.* (2017). Quantitative and qualitative  
1110 iNKT repertoire associations with disease susceptibility and outcome in macaque  
1111 tuberculosis infection. *Tuberculosis (Edinb)* 105, 86-95.
- 1112 Chen, C.Y., Huang, D., Wang, R.C., Shen, L., Zeng, G., Yao, S., Shen, Y., Halliday, L.,  
1113 Fortman, J., McAllister, M., *et al.* (2009). A critical role for CD8 T cells in a nonhuman  
1114 primate model of tuberculosis. *PLoS Pathog* 5, e1000392.



- 1115 Coleman, M.T., Chen, R.Y., Lee, M., Lin, P.L., Dodd, L.E., Maiello, P., Via, L.E., Kim,  
1116 Y., Marriner, G., Dartois, V., *et al.* (2014a). PET/CT imaging reveals a therapeutic  
1117 response to oxazolidinones in macaques and humans with tuberculosis. *Sci Transl Med*  
1118 **6**, 265ra167.
- 1119 Coleman, M.T., Maiello, P., Tomko, J., Frye, L.J., Fillmore, D., Janssen, C., Klein, E.,  
1120 and Lin, P.L. (2014b). Early Changes by (18)Fluorodeoxyglucose positron emission  
1121 tomography coregistered with computed tomography predict outcome after  
1122 *Mycobacterium tuberculosis* infection in cynomolgus macaques. *Infect Immun* **82**, 2400-  
1123 2404.
- 1124 Darrah, P.A., Zeppa, J.J., Maiello, P., Hackney, J.A., Wadsworth, M.H., 2nd, Hughes,  
1125 T.K., Pokkali, S., Swanson, P.A., 2nd, Grant, N.L., Rodgers, M.A., *et al.* (2020).  
1126 Prevention of tuberculosis in macaques after intravenous BCG immunization. *Nature*  
1127 **577**, 95-102.
- 1128 Diedrich, C.R., Rutledge, T., Maiello, P., Baranowski, T.M., White, A.G., Borish, H.J.,  
1129 Karell, P., Hopkins, F., Brown, J., Fortune, S.M., *et al.* (2020). SIV and *Mycobacterium*  
1130 *tuberculosis* synergy within the granuloma accelerates the reactivation pattern of latent  
1131 tuberculosis. bioRxiv.
- 1132 Dijkman, K., Sombroek, C.C., Vervenne, R.A.W., Hofman, S.O., Boot, C., Remarque,  
1133 E.J., Kocken, C.H.M., Ottenhoff, T.H.M., Kondova, I., Khayum, M.A., *et al.* (2019).  
1134 Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed  
1135 rhesus macaques. *Nat Med* **25**, 255-262.
- 1136 Ehlers, S., and Schaible, U.E. (2012). The granuloma in tuberculosis: dynamics of a  
1137 host-pathogen collusion. *Front Immunol* **3**, 411.
- 1138 Fan, X., and Rudensky, A.Y. (2016). Hallmarks of Tissue-Resident Lymphocytes. *Cell*  
1139 **164**, 1198-1211.
- 1140 Flynn, J.L. (2006). Lessons from experimental *Mycobacterium tuberculosis* infections.  
1141 *Microbes Infect* **8**, 1179-1188.
- 1142 Flynn, J.L., Capuano, S.V., Croix, D., Pawar, S., Myers, A., Zinovik, A., and Klein, E.  
1143 (2003). Non-human primates: a model for tuberculosis research. *Tuberculosis (Edinb)*  
1144 **83**, 116-118.
- 1145 Flynn, J.L., Gideon, H.P., Mattila, J.T., and Lin, P.L. (2015). Immunology studies in non-  
1146 human primate models of tuberculosis. *Immunol Rev* **264**, 60-73.
- 1147 Flynn, J.L., Klein, E., (2010). Pulmonary Tuberculosis in Monkeys. *A Color Atlas of*  
1148 *Comparative Pathology of Pulmonary Tuberculosis*, 83-105.
- 1149 Foreman, T.W., Mehra, S., LoBato, D.N., Malek, A., Alvarez, X., Golden, N.A., Bucsan,  
1150 A.N., Didier, P.J., Doyle-Meyers, L.A., Russell-Lodrigue, K.E., *et al.* (2016). CD4+ T-



- 1151 cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque  
1152 model of HIV coinfection. *Proc Natl Acad Sci U S A* *113*, E5636-5644.
- 1153 Fuertes Marraco, S.A., Soneson, C., Delorenzi, M., and Speiser, D.E. (2015). Genome-  
1154 wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow  
1155 Fever vaccination in humans. *Genom Data* *5*, 297-301.
- 1156 Garcia-Rodriguez, K.M., Goenka, A., Alonso-Rasgado, M.T., Hernandez-Pando, R., and  
1157 Bulfone-Paus, S. (2017). The Role of Mast Cells in Tuberculosis: Orchestrating Innate  
1158 Immune Crosstalk? *Front Immunol* *8*, 1290.
- 1159 Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R.,  
1160 Gostick, E., Yu, Z., Carpenito, C., *et al.* (2011). A human memory T cell subset with  
1161 stem cell-like properties. *Nat Med* *17*, 1290-1297.
- 1162 Gideon, H.P., Phuah, J., Junecko, B.A., and Mattila, J.T. (2019). Neutrophils express  
1163 pro- and anti-inflammatory cytokines in granulomas from Mycobacterium tuberculosis-  
1164 infected cynomolgus macaques. *Mucosal Immunol* *12*, 1370-1381.
- 1165 Gideon, H.P., Phuah, J., Myers, A.J., Bryson, B.D., Rodgers, M.A., Coleman, M.T.,  
1166 Maiello, P., Rutledge, T., Marino, S., Fortune, S.M., *et al.* (2015). Variability in  
1167 tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-  
1168 inflammatory cytokines is associated with sterilization. *PLoS Pathog* *11*, e1004603.
- 1169 Gierahn, T.M., Wadsworth, M.H., 2nd, Hughes, T.K., Bryson, B.D., Butler, A., Satija, R.,  
1170 Fortune, S., Love, J.C., and Shalek, A.K. (2017). Seq-Well: portable, low-cost RNA  
1171 sequencing of single cells at high throughput. *Nat Methods* *14*, 395-398.
- 1172 Green, A.M., Difazio, R., and Flynn, J.L. (2013). IFN-gamma from CD4 T cells is  
1173 essential for host survival and enhances CD8 T cell function during Mycobacterium  
1174 tuberculosis infection. *J Immunol* *190*, 270-277.
- 1175 Guo, Y., Chen, J., Shi, L., and Fan, Z. (2010). Valosin-containing protein cleavage by  
1176 granzyme K accelerates an endoplasmic reticulum stress leading to caspase-  
1177 independent cytotoxicity of target tumor cells. *J Immunol* *185*, 5348-5359.
- 1178 Han, X., Wang, R., Zhou, Y., Fei, L., Sun, H., Lai, S., Saadatpour, A., Zhou, Z., Chen,  
1179 H., Ye, F., *et al.* (2018). Mapping the Mouse Cell Atlas by Microwell-Seq. *Cell* *173*,  
1180 1307.
- 1181 Hirota, K., Yoshitomi, H., Hashimoto, M., Maeda, S., Teradaira, S., Sugimoto, N.,  
1182 Yamaguchi, T., Nomura, T., Ito, H., Nakamura, T., *et al.* (2007). Preferential recruitment  
1183 of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and  
1184 its animal model. *J Exp Med* *204*, 2803-2812.
- 1185 Hovestadt, V., Smith, K.S., Bihannic, L., Filbin, M.G., Shaw, M.L., Baumgartner, A.,  
1186 DeWitt, J.C., Groves, A., Mayr, L., Weisman, H.R., *et al.* (2019). Resolving  
1187 medulloblastoma cellular architecture by single-cell genomics. *Nature* *572*, 74-79.

- 1188 Hu, S., Lv, P., Yan, Z., and Wen, B. (2019). Disruption of nuclear speckles reduces  
1189 chromatin interactions in active compartments. *Epigenetics Chromatin* 12, 43.
- 1190 Huang, H., Sikora, M.J., Islam, S., Chowdhury, R.R., Chien, Y.H., Scriba, T.J., Davis,  
1191 M.M., and Steinmetz, L.M. (2019). Select sequencing of clonally expanded CD8(+) T  
1192 cells reveals limits to clonal expansion. *Proc Natl Acad Sci U S A* 116, 8995-9001.
- 1193 Hunter, R.L. (2011). Pathology of post primary tuberculosis of the lung: an illustrated  
1194 critical review. *Tuberculosis (Edinb)* 91, 497-509.
- 1195 Hunter, R.L. (2016). Tuberculosis as a three-act play: A new paradigm for the  
1196 pathogenesis of pulmonary tuberculosis. *Tuberculosis (Edinb)* 97, 8-17.
- 1197 Huynh, J.P., Lin, C.C., Kimmey, J.M., Jarjour, N.N., Schwarzkopf, E.A., Bradstreet,  
1198 T.R., Shchukina, I., Shpynov, O., Weaver, C.T., Taneja, R., *et al.* (2018). Bhlhe40 is an  
1199 essential repressor of IL-10 during Mycobacterium tuberculosis infection. *J Exp Med*  
1200 215, 1823-1838.
- 1201 Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelletier, A., Lafaille, J.J., Cua,  
1202 D.J., and Littman, D.R. (2006). The orphan nuclear receptor ROR $\gamma$  directs the  
1203 differentiation program of proinflammatory IL-17+ T helper cells. *Cell* 126, 1121-1133.
- 1204 Iwasaki, A., and Medzhitov, R. (2015). Control of adaptive immunity by the innate  
1205 immune system. *Nat Immunol* 16, 343-353.
- 1206 Jacobs, A.J., Mongkolsapaya, J., Screaton, G.R., McShane, H., and Wilkinson, R.J.  
1207 (2016). Antibodies and tuberculosis. *Tuberculosis (Edinb)* 101, 102-113.
- 1208 Jayaraman, P., Jacques, M.K., Zhu, C., Steblenko, K.M., Stowell, B.L., Madi, A.,  
1209 Anderson, A.C., Kuchroo, V.K., and Behar, S.M. (2016). TIM3 Mediates T Cell  
1210 Exhaustion during Mycobacterium tuberculosis Infection. *PLoS Pathog* 12, e1005490.
- 1211 Joosten, S.A., Ottenhoff, T.H.M., Lewinsohn, D.M., Hoft, D.F., Moody, D.B., Seshadri,  
1212 C., Collaboration for Tuberculosis Vaccine Discovery - Donor-Unrestricted T-cells  
1213 Working Group, B., and Melinda Gates, F. (2019). Harnessing donor unrestricted T-cells  
1214 for new vaccines against tuberculosis. *Vaccine* 37, 3022-3030.
- 1215 Kazer, S.W., Aicher, T.P., Muema, D.M., Carroll, S.L., Ordovas-Montanes, J., Miao,  
1216 V.N., Tu, A.A., Ziegler, C.G.K., Nyquist, S.K., Wong, E.B., *et al.* (2020). Integrated  
1217 single-cell analysis of multicellular immune dynamics during hyperacute HIV-1 infection.  
1218 *Nat Med* 26, 511-518.
- 1219 Khader, S.A., Bell, G.K., Pearl, J.E., Fountain, J.J., Rangel-Moreno, J., Cilley, G.E.,  
1220 Shen, F., Eaton, S.M., Gaffen, S.L., Swain, S.L., *et al.* (2007). IL-23 and IL-17 in the  
1221 establishment of protective pulmonary CD4+ T cell responses after vaccination and  
1222 during Mycobacterium tuberculosis challenge. *Nat Immunol* 8, 369-377.

- 1223 Khader, S.A., and Gopal, R. (2010). IL-17 in protective immunity to intracellular  
1224 pathogens. *Virulence* 1, 423-427.
- 1225 Khan, N., Vidyarthi, A., Amir, M., Mushtaq, K., and Agrewala, J.N. (2017). T-cell  
1226 exhaustion in tuberculosis: pitfalls and prospects. *Crit Rev Microbiol* 43, 133-141.
- 1227 Kienzle, N., Olver, S., Buttigieg, K., Groves, P., Janas, M.L., Baz, A., and Kelso, A.  
1228 (2005). Progressive differentiation and commitment of CD8+ T cells to a poorly cytolytic  
1229 CD8low phenotype in the presence of IL-4. *J Immunol* 174, 2021-2029.
- 1230 Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R.,  
1231 Kitazume, M.T., Nakazawa, A., Sugita, A., Koganei, K., *et al.* (2008). IL23 differentially  
1232 regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. *Gut* 57, 1682-  
1233 1689.
- 1234 Langermans, J.A., Andersen, P., van Soolingen, D., Vervenne, R.A., Frost, P.A., van  
1235 der Laan, T., van Pinxteren, L.A., van den Hombergh, J., Kroon, S., Peekel, I., *et al.*  
1236 (2001). Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on  
1237 *Mycobacterium tuberculosis* infection in highly related macaque species: implications for  
1238 primate models in tuberculosis vaccine research. *Proc Natl Acad Sci U S A* 98, 11497-  
1239 11502.
- 1240 Lenaerts, A., Barry, C.E., 3rd, and Dartois, V. (2015). Heterogeneity in tuberculosis  
1241 pathology, microenvironments and therapeutic responses. *Immunol Rev* 264, 288-307.
- 1242 Liang, Y., Pan, H.F., and Ye, D.Q. (2015). Tc17 Cells in Immunity and Systemic  
1243 Autoimmunity. *Int Rev Immunol* 34, 318-331.
- 1244 Lin, C.C., Bradstreet, T.R., Schwarzkopf, E.A., Jarjour, N.N., Chou, C., Archambault,  
1245 A.S., Sim, J., Zinselmeyer, B.H., Carrero, J.A., Wu, G.F., *et al.* (2016). IL-1-induced  
1246 Bhlhe40 identifies pathogenic T helper cells in a model of autoimmune  
1247 neuroinflammation. *J Exp Med* 213, 251-271.
- 1248 Lin, C.C., Bradstreet, T.R., Schwarzkopf, E.A., Sim, J., Carrero, J.A., Chou, C., Cook,  
1249 L.E., Egawa, T., Taneja, R., Murphy, T.L., *et al.* (2014a). Bhlhe40 controls cytokine  
1250 production by T cells and is essential for pathogenicity in autoimmune  
1251 neuroinflammation. *Nat Commun* 5, 3551.
- 1252 Lin, P.L., Coleman, T., Carney, J.P., Lopresti, B.J., Tomko, J., Fillmore, D., Dartois, V.,  
1253 Scanga, C., Frye, L.J., Janssen, C., *et al.* (2013). Radiologic Responses in *Cynomolgus*  
1254 *Macaques* for Assessing Tuberculosis Chemotherapy Regimens. *Antimicrob Agents*  
1255 *Chemother* 57, 4237-4244.
- 1256 Lin, P.L., and Flynn, J.L. (2015). CD8 T cells and *Mycobacterium tuberculosis* infection.  
1257 *Semin Immunopathol* 37, 239-249.
- 1258 Lin, P.L., Ford, C.B., Coleman, M.T., Myers, A.J., Gawande, R., Ioerger, T., Sacchetti,  
1259 J., Fortune, S.M., and Flynn, J.L. (2014b). Sterilization of granulomas is common in

- 1260 active and latent tuberculosis despite within-host variability in bacterial killing. *Nat Med*  
1261 *20*, 75-79.
- 1262 Lin, P.L., Myers, A., Smith, L., Bigbee, C., Bigbee, M., Fuhrman, C., Grieser, H.,  
1263 Chiosea, I., Voitenek, N.N., Capuano, S.V., *et al.* (2010). Tumor necrosis factor  
1264 neutralization results in disseminated disease in acute and latent *Mycobacterium*  
1265 tuberculosis infection with normal granuloma structure in a cynomolgus macaque  
1266 model. *Arthritis Rheum* *62*, 340-350.
- 1267 Lin, P.L., Pawar, S., Myers, A., Pegu, A., Fuhrman, C., Reinhart, T.A., Capuano, S.V.,  
1268 Klein, E., and Flynn, J.L. (2006). Early events in *Mycobacterium tuberculosis* infection in  
1269 cynomolgus macaques. *Infect Immun* *74*, 3790-3803.
- 1270 Lin, P.L., Plessner, H.L., Voitenok, N.N., and Flynn, J.L. (2007). Tumor necrosis factor  
1271 and tuberculosis. *J Investig Dermatol Symp Proc* *12*, 22-25.
- 1272 Lin, P.L., Rodgers, M., Smith, L., Bigbee, M., Myers, A., Bigbee, C., Chiosea, I.,  
1273 Capuano, S.V., Fuhrman, C., Klein, E., *et al.* (2009). Quantitative comparison of active  
1274 and latent tuberculosis in the cynomolgus macaque model. *Infect Immun* *77*, 4631-  
1275 4642.
- 1276 Lin, P.L., Rutledge, T., Green, A.M., Bigbee, M., Fuhrman, C., Klein, E., and Flynn, J.L.  
1277 (2012). CD4 T cell depletion exacerbates acute *Mycobacterium tuberculosis* while  
1278 reactivation of latent infection is dependent on severity of tissue depletion in  
1279 cynomolgus macaques. *AIDS Res Hum Retroviruses* *28*, 1693-1702.
- 1280 Lopez, D., Montoya, D., Ambrose, M., Lam, L., Briscoe, L., Adams, C., Modlin, R.L., and  
1281 Pellegrini, M. (2017). SaVanT: a web-based tool for the sample-level visualization of  
1282 molecular signatures in gene expression profiles. *BMC Genomics* *18*, 824.
- 1283 Lu, L.L., Chung, A.W., Rosebrock, T.R., Ghebremichael, M., Yu, W.H., Grace, P.S.,  
1284 Schoen, M.K., Tafesse, F., Martin, C., Leung, V., *et al.* (2016). A Functional Role for  
1285 Antibodies in Tuberculosis. *Cell* *167*, 433-443 e414.
- 1286 Lyadova, I.V., and Panteleev, A.V. (2015). Th1 and Th17 Cells in Tuberculosis:  
1287 Protection, Pathology, and Biomarkers. *Mediators Inflamm* *2015*, 854507.
- 1288 Maiello, P., DiFazio, R.M., Cadena, A.M., Rodgers, M.A., Lin, P.L., Scanga, C.A., and  
1289 Flynn, J.L. (2018). Rhesus Macaques Are More Susceptible to Progressive  
1290 Tuberculosis than Cynomolgus Macaques: a Quantitative Comparison. *Infect Immun*  
1291 *86*.
- 1292 Malherbe, S.T., Shenai, S., Ronacher, K., Loxton, A.G., Dolganov, G., Kriel, M., Van, T.,  
1293 Chen, R.Y., Warwick, J., Via, L.E., *et al.* (2016). Persisting positron emission  
1294 tomography lesion activity and *Mycobacterium tuberculosis* mRNA after tuberculosis  
1295 cure. *Nat Med* *22*, 1094-1100.

- 1296 Martin, C.J., Cadena, A.M., Leung, V.W., Lin, P.L., Maiello, P., Hicks, N., Chase, M.R.,  
1297 Flynn, J.L., and Fortune, S.M. (2017). Digitally Barcoding Mycobacterium tuberculosis  
1298 Reveals In Vivo Infection Dynamics in the Macaque Model of Tuberculosis. *mBio* 8.
- 1299 Mateus, J., Lasso, P., Pavia, P., Rosas, F., Roa, N., Valencia-Hernandez, C.A.,  
1300 Gonzalez, J.M., Puerta, C.J., and Cuellar, A. (2015). Low frequency of circulating CD8+  
1301 T stem cell memory cells in chronic chagasic patients with severe forms of the disease.  
1302 *PLoS Negl Trop Dis* 9, e3432.
- 1303 Mattila, J.T., Diedrich, C.R., Lin, P.L., Phuah, J., and Flynn, J.L. (2011). Simian  
1304 immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus  
1305 macaques with latent Mycobacterium tuberculosis infection are associated with timing of  
1306 reactivation. *J Immunol* 186, 3527-3537.
- 1307 Mattila, J.T., Maiello, P., Sun, T., Via, L.E., and Flynn, J.L. (2015). Granzyme B-  
1308 expressing neutrophils correlate with bacterial load in granulomas from Mycobacterium  
1309 tuberculosis-infected cynomolgus macaques. *Cell Microbiol* 17, 1085-1097.
- 1310 Mattila, J.T., Ojo, O.O., Kepka-Lenhart, D., Marino, S., Kim, J.H., Eum, S.Y., Via, L.E.,  
1311 Barry, C.E., 3rd, Klein, E., Kirschner, D.E., *et al.* (2013). Microenvironments in  
1312 tuberculous granulomas are delineated by distinct populations of macrophage subsets  
1313 and expression of nitric oxide synthase and arginase isoforms. *J Immunol* 191, 773-784.
- 1314 McCaffrey, E.F., Donato, M., Keren, L., Chen, Z., Fitzpatrick, M., Jojic, V., Delmastro,  
1315 A., Greenwald, N.F., Baranski, A., Graf, W., *et al.* (2020). Multiplexed imaging of human  
1316 tuberculosis granulomas uncovers immunoregulatory features conserved across tissue  
1317 and blood. *bioRxiv*, 2020.2006.2008.140426.
- 1318 Meyer Zu Horste, G., Wu, C., Wang, C., Cong, L., Pawlak, M., Lee, Y., Elyaman, W.,  
1319 Xiao, S., Regev, A., and Kuchroo, V.K. (2016). RBPJ Controls Development of  
1320 Pathogenic Th17 Cells by Regulating IL-23 Receptor Expression. *Cell Rep* 16, 392-404.
- 1321 Millington, K.A., Innes, J.A., Hackforth, S., Hinks, T.S., Deeks, J.J., Dosanjh, D.P.,  
1322 Guyot-Revol, V., Gunatheesan, R., Klenerman, P., and Lalvani, A. (2007). Dynamic  
1323 relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-  
1324 specific T cells and antigen load. *J Immunol* 178, 5217-5226.
- 1325 Mogue, T., Goodrich, M.E., Ryan, L., LaCourse, R., and North, R.J. (2001). The  
1326 relative importance of T cell subsets in immunity and immunopathology of airborne  
1327 Mycobacterium tuberculosis infection in mice. *J Exp Med* 193, 271-280.
- 1328 Montoro, D.T., Haber, A.L., Biton, M., Vinarsky, V., Lin, B., Birket, S.E., Yuan, F., Chen,  
1329 S., Leung, H.M., Villoria, J., *et al.* (2018). A revised airway epithelial hierarchy includes  
1330 CFTR-expressing ionocytes. *Nature* 560, 319-324.
- 1331 Mpande, C.A.M., Dintwe, O.B., Musvosvi, M., Mabwe, S., Bilek, N., Hatherill, M.,  
1332 Nemes, E., Scriba, T.J., and Team, S.C.I. (2018). Functional, Antigen-Specific Stem



- 1333 Cell Memory (TSCM) CD4(+) T Cells Are Induced by Human Mycobacterium  
1334 tuberculosis Infection. *Front Immunol* 9, 324.
- 1335 Munoz-Elias, E.J., Timm, J., Botha, T., Chan, W.T., Gomez, J.E., and McKinney, J.D.  
1336 (2005). Replication dynamics of Mycobacterium tuberculosis in chronically infected  
1337 mice. *Infect Immun* 73, 546-551.
- 1338 Nathan, A., Beynor, J.I., Baglaenko, Y., Suliman, S., Ishigaki, K., Asgari, S., Huang, C.-  
1339 C., Luo, Y., Zhang, Z., Tamara, K.L., *et al.* (2020). Multimodal memory T cell profiling  
1340 identifies a reduction in a polyfunctional Th17 state associated with tuberculosis  
1341 progression. *bioRxiv*, 2020.2004.2023.057828.
- 1342 Niedzielska, M., Israelsson, E., Angermann, B., Sidders, B.S., Clausen, M., Catley, M.,  
1343 Malhotra, R., and Dumont, C. (2018). Differential gene expression in human tissue  
1344 resident regulatory T cells from lung, colon, and blood. *Oncotarget* 9, 36166-36184.
- 1345 O'Garra, A., Redford, P.S., McNab, F.W., Bloom, C.I., Wilkinson, R.J., and Berry, M.P.  
1346 (2013). The immune response in tuberculosis. *Annu Rev Immunol* 31, 475-527.
- 1347 Ogongo, P., Steyn, A.J., Karim, F., Dullabh, K.J., Awala, I., Madansein, R., Leslie, A.,  
1348 and Behar, S.M. (2020). Differential skewing of donor-unrestricted and gammadelta T  
1349 cell repertoires in tuberculosis-infected human lungs. *J Clin Invest* 130, 214-230.
- 1350 Ohtani, H. (2013). Granuloma cells in chronic inflammation express CD205 (DEC205)  
1351 antigen and harbor proliferating T lymphocytes: similarity to antigen-presenting cells.  
1352 *Pathol Int* 63, 85-93.
- 1353 Ordovas-Montanes, J., Dwyer, D.F., Nyquist, S.K., Buchheit, K.M., Vukovic, M., Deb,  
1354 C., Wadsworth, M.H., 2nd, Hughes, T.K., Kazer, S.W., Yoshimoto, E., *et al.* (2018).  
1355 Allergic inflammatory memory in human respiratory epithelial progenitor cells. *Nature*  
1356 560, 649-654.
- 1357 Pagan, A.J., and Ramakrishnan, L. (2014). Immunity and Immunopathology in the  
1358 Tuberculous Granuloma. *Cold Spring Harb Perspect Med* 5.
- 1359 Phuah, J., Wong, E.A., Gideon, H.P., Maiello, P., Coleman, M.T., Hendricks, M.R.,  
1360 Ruden, R., Cirrincione, L.R., Chan, J., Lin, P.L., *et al.* (2016). Effects of B Cell Depletion  
1361 on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques. *Infect Immun*  
1362 84, 1301-1311.
- 1363 Phuah, J.Y., Mattila, J.T., Lin, P.L., and Flynn, J.L. (2012). Activated B cells in the  
1364 granulomas of nonhuman primates infected with Mycobacterium tuberculosis. *Am J*  
1365 *Pathol* 181, 508-514.
- 1366 Portevin, D., Via, L.E., Eum, S., and Young, D. (2012). Natural killer cells are recruited  
1367 during pulmonary tuberculosis and their ex vivo responses to mycobacteria vary  
1368 between healthy human donors in association with KIR haplotype. *Cell Microbiol* 14,  
1369 1734-1744.

- 1370 Prakadan, S.M., Shalek, A.K., and Weitz, D.A. (2017). Scaling by shrinking:  
1371 empowering single-cell 'omics' with microfluidic devices. *Nat Rev Genet* 18, 345-361.
- 1372 Raphael, I., Nalawade, S., Eagar, T.N., and Forsthuber, T.G. (2015). T cell subsets and  
1373 their signature cytokines in autoimmune and inflammatory diseases. *Cytokine* 74, 5-17.
- 1374 Reece, S.T., and Kaufmann, S.H. (2012). Floating between the poles of pathology and  
1375 protection: can we pin down the granuloma in tuberculosis? *Curr Opin Microbiol* 15, 63-  
1376 70.
- 1377 Rodrigues, M., Kosaric, N., Bonham, C.A., and Gurtner, G.C. (2019). Wound Healing: A  
1378 Cellular Perspective. *Physiol Rev* 99, 665-706.
- 1379 Roy Chowdhury, R., Vallania, F., Yang, Q., Lopez Angel, C.J., Darboe, F., Penn-  
1380 Nicholson, A., Rozot, V., Nemes, E., Malherbe, S.T., Ronacher, K., *et al.* (2018). Author  
1381 Correction: A multi-cohort study of the immune factors associated with M. tuberculosis  
1382 infection outcomes. *Nature* 564, E5.
- 1383 Rubinchik, E., and Levi-Schaffer, F. (1994). Mast cells and fibroblasts: two interacting  
1384 cells. *Int J Clin Lab Res* 24, 139-142.
- 1385 Russell, D.G., Barry, C.E., 3rd, and Flynn, J.L. (2010). Tuberculosis: what we don't  
1386 know can, and does, hurt us. *Science* 328, 852-856.
- 1387 Sakai, S., Kauffman, K.D., Sallin, M.A., Sharpe, A.H., Young, H.A., Ganusov, V.V., and  
1388 Barber, D.L. (2016). CD4 T Cell-Derived IFN-gamma Plays a Minimal Role in Control of  
1389 Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by  
1390 PD-1 to Prevent Lethal Disease. *PLoS Pathog* 12, e1005667.
- 1391 Schietinger, A., Delrow, J.J., Basom, R.S., Blattman, J.N., and Greenberg, P.D. (2012).  
1392 Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.  
1393 *Science* 335, 723-727.
- 1394 Scriba, T.J., Coussens, A.K., and Fletcher, H.A. (2017). Human Immunology of  
1395 Tuberculosis. *Microbiol Spectr* 5.
- 1396 Shehadeh, L.A., Yu, K., Wang, L., Guevara, A., Singer, C., Vance, J., and  
1397 Papapetropoulos, S. (2010). SRRM2, a potential blood biomarker revealing high  
1398 alternative splicing in Parkinson's disease. *PLoS One* 5, e9104.
- 1399 Shen, L., Frencher, J., Huang, D., Wang, W., Yang, E., Chen, C.Y., Zhang, Z., Wang,  
1400 R., Qaqish, A., Larsen, M.H., *et al.* (2019). Immunization of Vgamma2Vdelta2 T cells  
1401 programs sustained effector memory responses that control tuberculosis in nonhuman  
1402 primates. *Proc Natl Acad Sci U S A* 116, 6371-6378.
- 1403 Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S.A., Calderon-Copete, S.,  
1404 Pais Ferreira, D., Carmona, S.J., Scarpellino, L., Gfeller, D., Pradervand, S., *et al.*  
1405 (2019). Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote


- 1406 Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.  
1407 *Immunity* *50*, 195-211 e110.
- 1408 Smillie, C.S., Biton, M., Ordovas-Montanes, J., Sullivan, K.M., Burgin, G., Graham,  
1409 D.B., Herbst, R.H., Rogel, N., Slyper, M., Waldman, J., *et al.* (2019). Intra- and Inter-  
1410 cellular Rewiring of the Human Colon during Ulcerative Colitis. *Cell* *178*, 714-730 e722.
- 1411 Szabo, P.A., Levitin, H.M., Miron, M., Snyder, M.E., Senda, T., Yuan, J., Cheng, Y.L.,  
1412 Bush, E.C., Dogra, P., Thapa, P., *et al.* (2019). Single-cell transcriptomics of human T  
1413 cells reveals tissue and activation signatures in health and disease. *Nat Commun* *10*,  
1414 4706.
- 1415 Tabula Muris, C., Overall, c., Logistical, c., Organ, c., processing, Library, p.,  
1416 sequencing, Computational data, a., Cell type, a., Writing, g., *et al.* (2018). Single-cell  
1417 transcriptomics of 20 mouse organs creates a Tabula Muris. *Nature* *562*, 367-372.
- 1418 Takeuchi, M., Ohno, K., Takata, K., Gion, Y., Tachibana, T., Orita, Y., Yoshino, T., and  
1419 Sato, Y. (2015). Interleukin 13-positive mast cells are increased in immunoglobulin G4-  
1420 related sialadenitis. *Sci Rep* *5*, 7696.
- 1421 Taweewisit, M., and Pomsuk, U. (2007). High mast cell density associated with  
1422 granulomatous formation in tuberculous lymphadenitis. *Southeast Asian J Trop Med*  
1423 *Public Health* *38*, 115-119.
- 1424 Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H., 2nd, Treacy, D., Trombetta, J.J.,  
1425 Rotem, A., Rodman, C., Lian, C., Murphy, G., *et al.* (2016). Dissecting the multicellular  
1426 ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* *352*, 189-196.
- 1427 Tu, A.A., Gierahn, T.M., Monian, B., Morgan, D.M., Mehta, N.K., Rutter, B., Shreffler,  
1428 W.G., Shalek, A.K., and Love, J.C. (2019). TCR sequencing paired with massively  
1429 parallel 3' RNA-seq reveals clonotypic T cell signatures. *Nat Immunol* *20*, 1692-1699.
- 1430 Ulrichs, T., and Kaufmann, S.H. (2006). New insights into the function of granulomas in  
1431 human tuberculosis. *J Pathol* *208*, 261-269.
- 1432 van Hamburg, J.P., and Tas, S.W. (2018). Molecular mechanisms underpinning T  
1433 helper 17 cell heterogeneity and functions in rheumatoid arthritis. *J Autoimmun* *87*, 69-  
1434 81.
- 1435 Van Rhijn, I., Godfrey, D.I., Rossjohn, J., and Moody, D.B. (2015). Lipid and small-  
1436 molecule display by CD1 and MR1. *Nat Rev Immunol* *15*, 643-654.
- 1437 Verreck, F.A., Vervenne, R.A., Kondova, I., van Kralingen, K.W., Remarque, E.J.,  
1438 Braskamp, G., van der Werff, N.M., Kersbergen, A., Ottenhoff, T.H., Heidt, P.J., *et al.*  
1439 (2009). MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis  
1440 vaccine both show protective efficacy against tuberculosis in rhesus macaques. *PLoS*  
1441 *One* *4*, e5264.




- 1442 Wacleche, V.S., Goulet, J.P., Gosselin, A., Monteiro, P., Soudeyns, H., Fromentin, R.,  
1443 Jenabian, M.A., Vartanian, S., Deeks, S.G., Chomont, N., *et al.* (2016). New insights  
1444 into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during  
1445 antiretroviral therapy. *Retrovirology* 13, 59.
- 1446 Whibley, N., Tucci, A., and Powrie, F. (2019). Regulatory T cell adaptation in the  
1447 intestine and skin. *Nat Immunol* 20, 386-396.
- 1448 White, A.G., Maiello, P., Coleman, M.T., Tomko, J.A., Frye, L.J., Scanga, C.A., Lin,  
1449 P.L., and Flynn, J.L. (2017). Analysis of 18FDG PET/CT Imaging as a Tool for Studying  
1450 Mycobacterium tuberculosis Infection and Treatment in Non-human Primates. *J Vis*  
1451 *Exp*.
- 1452 WHO (2019). Global Tuberculosis Report.
- 1453 Wijesundara, D.K., Tschärke, D.C., Jackson, R.J., and Ranasinghe, C. (2013). Reduced  
1454 interleukin-4 receptor alpha expression on CD8+ T cells correlates with higher quality  
1455 anti-viral immunity. *PLoS One* 8, e55788.
- 1456 Wong, E.A., Evans, S., Kraus, C.R., Engelman, K.D., Maiello, P., Flores, W.J., Cadena,  
1457 A.M., Klein, E., Thomas, K., White, A.G., *et al.* (2020). IL-10 Impairs Local Immune  
1458 Response in Lung Granulomas and Lymph Nodes during Early Mycobacterium  
1459 tuberculosis Infection. *J Immunol* 204, 644-659.
- 1460 Wong, E.A., Joslyn, L., Grant, N.L., Klein, E., Lin, P.L., Kirschner, D.E., and Flynn, J.L.  
1461 (2018). Low Levels of T Cell Exhaustion in Tuberculous Lung Granulomas. *Infect*  
1462 *Immun* 86.
- 1463 Wu, C., Pot, C., Apetoh, L., Thalhammer, T., Zhu, B., Murugaiyan, G., Xiao, S., Lee, Y.,  
1464 Rangachari, M., Yosef, N., *et al.* (2013). Metallothioneins negatively regulate IL-27-  
1465 induced type 1 regulatory T-cell differentiation. *Proc Natl Acad Sci U S A* 110, 7802-  
1466 7807.
- 1467 Wu, K., Li, Y., Zhang, S., Zhou, N., Liu, B., Pan, T., Zhang, X., Luo, H., Huang, Z., Li,  
1468 X., *et al.* (2019). Preferential Homing of Tumor-specific and Functional CD8+ Stem Cell-  
1469 like Memory T Cells to the Bone Marrow. *J Immunother* 42, 197-207.
- 1470 Wulff, B.C., and Wilgus, T.A. (2013). Mast cell activity in the healing wound: more than  
1471 meets the eye? *Exp Dermatol* 22, 507-510.
- 1472 Yang, X.O., Nurieva, R., Martinez, G.J., Kang, H.S., Chung, Y., Pappu, B.P., Shah, B.,  
1473 Chang, S.H., Schluns, K.S., Watowich, S.S., *et al.* (2008). Molecular antagonism and  
1474 plasticity of regulatory and inflammatory T cell programs. *Immunity* 29, 44-56.
- 1475 Yosef, N., Shalek, A.K., Gaublomme, J.T., Jin, H., Lee, Y., Awasthi, A., Wu, C.,  
1476 Karwacz, K., Xiao, S., Jorgolli, M., *et al.* (2013). Dynamic regulatory network controlling  
1477 TH17 cell differentiation. *Nature* 496, 461-468.

- 1478 Zemmour, D., Zilionis, R., Kiner, E., Klein, A.M., Mathis, D., and Benoist, C. (2018).  
1479 Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped  
1480 by the TCR. *Nat Immunol* 19, 291-301.
- 1481 Zhan, L., Tang, J., Sun, M., and Qin, C. (2017). Animal Models for Tuberculosis in  
1482 Translational and Precision Medicine. *Front Microbiol* 8, 717.
- 1483 Zilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H.D.,  
1484 Krishnan, I., Maroni, G., Meyerovitz, C.V., Kerwin, C.M., *et al.* (2019). Single-Cell  
1485 Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid  
1486 Populations across Individuals and Species. *Immunity* 50, 1317-1334 e1310.  
1487


A




B




C




D




E




F



G




## Figure 2







A




B




C




D



A




B




● Sub-Population 1 ● Sub-Population 3  
● Sub-Population 2 ● Sub-Population 4


C




D



E







## Figure 6

